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The repair of complex bone defects remains a surgical challenge and it is hoped that 
tissue-engineering may offer an unlimited source of bone tissue and circumvent many 
of the drawbacks associated with current clinical approaches. Currently, the majority of 
bone tissue-engineering research has been focused on the differentiation of 
mesenchymal stem cells (MSCs) into osteoblasts. Tissue-engineering via the 
endochondral ossification pathway to prepare a hypertrophic cartilage graft, however, 
may be a more advantageous approach. This tissue is able to survive the relatively low 
oxygen tensions found in defects and it may provide growth factors that promote 
angiogenesis and bone tissue regeneration. Surprisingly little research has been 
directed at hypertrophic cartilage engineering. The aim of this project was therefore to 
investigate the ability of nasal chondrocytes to form a hypertrophic cartilage graft 
capable of regenerating bone tissue in vivo.  
The methodology used in this study was based on the typical tissue-engineering 
approach and encompassed scaffold fabrication, tissue characterisation and in vivo 
studies. Rat nasal chondrocytes consistently differentiated to form hypertrophic 
cartilage grafts on both PGA and PLLA/calcium phosphate scaffold materials. These 
grafts expressed collagen type X and alkaline phosphatase, co-located with large 
chondrocytes, in a tissue that had morphological features in common with 
hypertrophic cartilage. Gene and protein expression studies demonstrated a decrease 
in hyaline cartilage markers and an increase in markers for hypertrophic chondrocytes 
as differentiation proceeded. Vital and decellularised grafts cultured on the PGA 
scaffold material significantly increased bone regeneration in vivo when compared to 
empty defects (4mm) in the rat cranium. Decellularised grafts that were reseeded with 
MSCs also promoted significant bone tissue regeneration after 12 weeks. This 
regeneration, however, occurred at a slower rate compared to the other grafts 
evaluated. Foetal calf serum (FCS) was shown to have a significant effect on the 
differentiation of the rat nasal chondrocytes. A defined, serum-free medium was 
therefore developed which was able to support the hypertrophic differentiation of the 
chondrocytes. Finally proof of concept studies demonstrated the ability of a Quasi-
vivo® bioreactor to support hypertrophic differentiation of nasal chondrocytes under 
flow conditions. It was concluded that nasal chondrocytes could be seeded onto 
scaffold materials and cultured under defined conditions to prepare a hypertrophic 
cartilage graft capable of stimulating bone tissue regeneration in vivo. The use of a 
decellularised hypertrophic cartilage demonstrated substantial clinical potential for use 
as a new regenerative graft material. 
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There is a high demand for graft materials to repair and regenerate bone tissue in a 
wide variety of conditions including fracture non-unions, congenital defects and 
trauma. Bone is the second most transplanted tissue, with around 2.2 million grafts 
being performed every year. Currently the ‘gold standard’ for the repair of bone tissue 
is an autograft, where bone is taken from a site within the patient and re-implanted 
into a defect. While generally giving the best clinical results, this method has 
drawbacks including as long-term post-operative pain and/or donor site morbidity. 
There is also a limit to the volume of bone which can be taken by autograft.  
Other methods have been used clinically including allografts and xenografts as well as 
osteoconductive biomaterials. Allografts and xenografts require a high degree of 
processing before they can be used, which decreases their osteoinductive potential 
and they have the added risk of disease transmission. Alloplastic biomaterials such as 
calcium phosphates are widely utilised, but they lack the osteogenic potential of 
autograft and the observed host response is not consistent. Therefore the repair of 
bone defects remains a challenge for surgeons and it is hoped that tissue-engineering 
will provide a new source of bone graft tissue for transplantation.  
The majority of bone tissue-engineering research has centred on the differentiation of 
adult stem cells into osteoblasts to form new tissue through the process of 
intramembranous ossification. The endochondral ossification pathway which involves 
the initial formation of a hypertrophic cartilage template, which is then remodelled 
into bone in vivo has until recently been neglected. Use of the endochondral pathway 
may, however, prove to be the tissue-engineering strategy of choice for bone 
regeneration. Development of most bones in the body and fracture repair commonly 
occurs via this pathway. The use of cartilage as a graft material is advantageous as it 
has the ability to survive in the relatively low oxygen concentrations typically found at 
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the graft site. Hypertrophic cartilage has also been reported to produce the biological 
molecules, such as vascular endothelial growth factor (VEGF) that could enable graft 
integration, blood vessel formation and the subsequent remodelling into bone. For 
these reasons, the use of a hypertrophic cartilage graft has the potential to become an 
alternative approach for the regeneration of bone. 
Previous research in this area has highlighted the potential of both MSCs and nasal 
chondrocytes to be a cell source for the production of hypertrophic chondrocyte grafts. 
Nasal chondrocytes, however, are an advantageous source due to their ease of 
isolation and high proliferation independent of patient age. Despite the compelling 
arguments that suggest that hypertrophic cartilage has a significant potential for the 
regeneration of bone in complex defects, surprisingly little research in this field has 
been reported to date. Therefore the aim of this research is to further investigate the 
ability of nasal chondrocytes to produce hypertrophic chondrocyte grafts and to assess 
their potential for the regeneration of bone in vivo. The specific objectives of this 
research can be found in section 3. 
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2 Literature Review 
2.1 Basic Bone Biology 
2.1.1  Function and Basic Structure 
Bone tissue constitutes the major load-bearing part of the endoskeleton of vertebrates 
and has a variety of functions within the body. It is essential not only for maintaining 
body structure and allowing for movement, but also for the physical protection of the 
internal organs and tissues. Bone is also able to store minerals, fat and growth factors 
which, if required, can be released (Clarke, 2008). The marrow found within the 
medullary cavities of the long bone and interstices of the cancellous bones is essential 
for haematopoiesis (blood cell production), as well as being a source for stem cell 
regeneration (Taichman, 2005). 
Bone structures consist of two major macrostructures, cancellous (trabecular) and 
cortical (compact) bone (Figure 2-1) (Rho et al., 1998). Cancellous bone is composed of 
trabecular struts, which leads to a honeycomb structure containing pores filled with 
bone marrow (Rho et al., 1998). This cancellous structure is found in the centre of the 
bone and the orientation of the trabecular struts allows it to withstand the stresses. 
Cancellous bone is also more metabolically-active than cortical bone and is re-
modelled by the osteoblasts, osteocytes and osteoclasts (Rho et al., 1998). Cortical 
bone has a more compact structure with a more defined architecture and is not as 
regularly remodelled.  
 




Figure 2-1: The structure of a long bone, showing the positioning of the cortical and 
cancellous bone as well as the positioning of the periosteum (Adapted from Rho et al 
(Rho et al., 1998)). 
The primary tissue of bone, osseous tissue, is hard but lightweight and mainly 
composed of the mineral, hydroxyapatite, and proteins of which collagen type I is the 
major component (Clarke, 2008). Bone has a high compressive strength, but poor 
tensile and shear stress strength (Table 2-1). These properties makes bone relatively 
brittle, however, it does possess some elasticity due to the high collagen content 
within the osseous tissue (Hutmacher et al., 2007). 
Table 2-1: The mechanical strengths of cortical and cancellous bone (Hutmacher et al., 
2007) 
 Cortical Bone Cancellous Bone 
Compressive Strength (MPa) 100-230 2-12 
Tensile Strength (MPa) 50-150 10-20 
Fracture Toughness (MPam1/2) 2-12 - 
Young’s Modulus (GPa) 7-30 0.5-0.05 
Cancellous Bone 
 Cortical Bone 
Periostieum 
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 The main cells found within bone tissue are osteoblasts, osteocytes and osteoclasts 
which are responsible for bone formation, maintenance and resorption respectively. 
Osteoblasts are mononucleated bone-forming cells, which are found on the active 
surfaces of bone and are derived from osteoprogenitors. They produce an osteoid (pre-
bone) extracellular matrix (ECM) which is mineralised to form new bone (Clarke, 2008). 
Once osteoblasts are entrapped within the mineralised matrix they then further 
differentiate into osteocytes. Osteocytes (mature bone cells) are found within lacunae 
in the bone and maintain the bone through ECM maintenance and calcium 
homeostasis (Bonewald, 1999). Finally osteoclasts are large multinucleated cells 
equipped with phagocyte-like mechanisms similar to macrophages. They are found in 
Howships lacunae on actively resorbing bone surfaces and slowly resorb bone (Boyle et 
al., 2003). 
2.1.2 Ossification 
Ossification is the process of bone formation during embryogenesis and skeletal 
development. It occurs via two pathways, intramembranous ossification and 
endochondral ossification. Intramembranous ossification is required for the formation 
of the ‘flat’ bones, such as the cranium (Ornitz and Marie, 2002), whereas 
endochondral ossification produces the long bones, such as the tibia.  
2.1.3  Intramembranous Ossification 
Intramembranous ossification revolves around the direct differentiation of 
mesenchymal stem cells (MSCs) into osteoblasts, forming the ‘flat’ bones of the skull. 
Initially MSCs condense to form compact nodules, producing an osteoid ECM as they 
differentiate into osteoblasts (Gilbert, 2000). Osteoblasts deposit a calcium-
proteoglycan ECM, which has the ability to bind calcium salts allowing for the initiation 
of calcification (Gawlitta et al., 2010). Calcification of the ECM proceeds in the form of 
bony spicules radiating from the osteoblasts. Once the osteoblasts are isolated within 
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the calcified ECM they further differentiate into osteocytes. When calcification is 
complete MSCs once again compact around the edges of the bone and differentiate to 
form the periosteum, depositing ECM parallel to the bone (Gilbert, 2000). 
Intramembranous ossification relies on the temporal expression of several growth 
factors and transcription factors. Bone morphogenic proteins (BMP), in particular 
BMP2, BMP4 and BMP7, are essential in ensuring the direct differentiation of neural 
crest-derived MSCs into osteoblasts (Gilbert, 2000). Transcription factor, runx2, is also 
important as it upregulates the expression of genes associated with ECM 
mineralisation, such as osteopontin and osteocalcin. Runx2 also has an effect on 
vascular endothelial growth factor (VEGF) expression, a key growth factor for attracting 
endothelial cells into the ECM enabling the formation of capillaries and the subsequent 
vascularisation of the bone (Carlevaro et al., 2000). This vascularisation of the bone is 
essential in intramembranous ossification as osteoblast require a high rate of nutrient 
exchange in order to survive (Hing, 2004). 
2.1.4 Endochondral Ossification 
The majority of the skeleton, including the axial and appendicular skeleton, is formed 
during embryogenesis through endochondral ossification (Wuelling and Vortkamp, 
2010). This method of ossification involves the formation of a hypertrophic cartilage 
template which calcifies and is remodelled into bone. Endochondral ossification and 
the chondrocyte differentiation pathway can be seen the growth plate of young 
children and adolescents (Figure 2-2). Proliferative columnar chondrocytes, which 
produce a complex hyaline-cartilage ECM, in which the predominant protein is collagen 
type II, These cells then undergo terminal differentiation into hypertrophic 
chondrocytes, which produce a mainly collagen type X ECM (Scotti et al., 2010, 
Gawlitta et al., 2010). 




Figure 2-2: Images of the growth plate of the rat, showing the different states of 
chondrocyte differentiation seen during endochondral ossification. (A) Haematoxylin 
and eosin staining to show the general cell morphology in the growth plate; (B) 
collagen type II localisation; (C) collagen type X localisation and (D) alkaline 
phosphatase localisation. (Images used with permission from Kwarciak (Kwarciak, 
2009)).  
During embryonic endochondral ossification MSCs condense in the area of bone 
formation and differentiate into two populations of chondrocytes, distal and columnar 
(Wuelling and Vortkamp, 2010). Distal chondrocytes proliferate at a low rate and form 
the articular cartilage which is found covering the ends of bones in the joints (Wuelling 
and Vortkamp, 2010). Columnar chondrocytes are responsible for bone formation and 
subsequent tissue growth within the growth plate. These columnar chondrocytes are 
transient, highly proliferative cells, which are organised into columns and can be found 
towards the centre of the bone (Wuelling and Vortkamp, 2010).  
Columnar chondrocytes have a specific morphology and produce a complex hyaline-
cartilage ECM, consisting of type II collagen, type IX collagen, type XI collagen, 
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aggrecan, chondronmodulin-1 and matrilin-3. Columnar chondrocytes also 
characteristically express the transcription factor SRY (sex determining region Y)-box 9 
(sox9), which works through the parathyroid hormone receptor pathway (PTHrP) to 
keep the chondrocytes in this proliferative state (Deschaseaux et al., 2009).  
Hypertrophy is the final differentiation state in chondrocyte differentiation. 
Hypertrophic chondrocytes are larger than the proliferative chondrocytes and produce 
a characteristic hypertrophic ECM, which includes collagen type X and alkaline 
phosphatase (Scotti et al., 2010, Gawlitta et al., 2010). Both of these ECM proteins 
have specific roles in the endochondral ossification process. Collagen type X plays an 
essential role in the entrapment and binding of matrix vesicles within the ECM as well 
as implementing an influx of calcium ions into the vesicles (Kirsch and Wuthier, 1994). 
A complete deletion of collagen type X in mice resulted in abnormal trabecular 
development and the under development of bones (Kwan et al., 1997, Chung et al., 
1997). Alkaline phosphatase has been shown to be expressed on the membranes of 
hypertrophic chondrocytes within the growth plate, with a complete deletion in mice 
resulting In the hypomineralisation of bones (Anderson et al., 2004). Alkaline 
phosphates is known to hydrolyse inorganic pyrophosphate (PPi), producing 
orthophosphate for mineral incorporation and reducing the inhibitory effect of PPi at 
the mineralisation site (Robison, 1926), (Fleisch et al., 1966).  
Endochondral ossification is tightly regulated by the several signalling molecules, 
growth factors and transcription factors. This regulation can be seen in Figure 2-3 and 
illustrates the importance of the temporal changes in the expression of these 
molecules in the differentiation of columnar chondrocytes into hypertrophic. Errors in 
this gene expression through gene mutations, can lead to developmental problems, 
such as dwarfism. 
 
 














Figure 2-3: Gene expression in the growth plate and their role in regulation of 
hypertrophic differentiation. 
 
Sox9, transforming growth factor-beta (TGF-β) and Indian hedgehog (Ihh) all work 
through the PTHrP pathway in order to keep the chondrocytes in a proliferative, 
columnar phenotype (Deschaseaux et al., 2009, Pateder et al., 2000, Mak et al., 2008). 
This expression of PTHrP keeps the chondrocytes in a proliferative state and is essential 
in the growth plate in order to maintain the width of the proliferative zone of the 
growth plate. Overexpression of PTHrP in mice leads to chondrodysplasia characterised 
by a delay in endochondral ossification and mice being born with cartilaginous 
endochondral skeleton (Weir et al., 1996). As mentioned above sox9 is highly 
expressed by proliferative chondrocytes within the growth plate, with a heterozygous 
deletion results in campomelic dysplasia, a severe form of dwarfism affecting all 
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articular cartilage tissue-engineering as it is well known to inhibit hypertrophic 
differentiation and downregulates collagen type X and alkaline phosphatase expression 
in cultured chondrocytes (Ferguson et al., 2000, Okeefe et al., 1988). As the 
chondrocytes start to differentiate, they take on a pre-hypertrophic phenotype, 
expressing signalling molecule Ihh. Ihh is essential at regulating the width of the growth 
plate in developing long bones as it is able to inhibit the further differentiation of 
proliferative chondrocytes in a dose dependant manor (Mak et al., 2008).  
Expression of transcription factor runx2 is essential to induce proliferative 
chondrocytes to exit the cell cycle and differentiate into hypertrophic chondrocytes 
(Deschaseaux et al., 2009). Runx2 is an essential transcription factor for several other 
key molecules required for mineralisation, including osteopontin, VEGF and specific 
matrix metalloproteinases (MMPs). MMPs are required for the breakdown of matrix 
proteins in order for mineralisation and remodelling into bone to occur (Vu et al., 
1998). MMP-13 is especially important during endochondral ossification as it breaks 
down the collagen type II initially laid down by the proliferative chondrocytes (Inada et 
al., 2004). Osteopontin is a non-collagenous bone matrix protein, which allows for 
osteoclast attachment to mineralised matrix, therefore allowing for matrix remodelling 
(Reinholt et al., 1990).   VEGF is essential for attracting endothelial cells and allowing 
for the ingrowth of blood vessels into the cartilage. Vascularisation of the tissue is 
essential for nutrient exchange within the tissue as well as delivering osteoblasts, 
osteoclasts and haematopoietic precursors (Scotti et al., 2010).  
The fate of the hypertrophic chondrocytes after terminal differentiation is highly 
debated (Shapiro et al., 2005). It is believed that some hypertrophic chondrocytes 
undergo apoptosis, characterised by DNA fragmentation and ultra-structural changes, 
leaving behind the ECM as a scaffold within which vascularisation and bone formation 
can occur (Zenmyo et al., 1996). It is also thought that some hypertrophic chondrocytes 
undergo “transdifferentiation” into bone-forming cells (Shapiro et al., 2005). However, 
definitive evidence of this process occurring in the growth plate is lacking with most 
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reports being circumstantial and based on microscopy examination of the chondro-
osseous junction (Shapiro et al., 2005). 
2.2   Bone Repair and Remodelling 
Unlike soft tissue injuries, which repair through the formation of fibrous scar tissue, 
bone defects heal through the formation of new bone which is indistinguishable from 
the uninjured tissue (Glowacki, 1998). The repair of the damaged bone resembles that 
of ossification during organogenesis and is comprised of a combination of both 
intramembranous and endochondral ossification (Dimitriou et al., 2005). When bones 
are fractured a complex cascade of events is required in order to restore the integrity 
of the bone. These events are essential in ensuring that the required cells (MSCs and 
osteoclasts) and soluble molecules (growth factors, cytokines, hormones and vitamins) 
are delivered to the injury site (Barnes et al., 1999, Bolander, 1992). 
The initial damage causes the disruption of blood vessels around the fracture, the 
coagulation of the subsequent internal bleeding leads to the formation of a 
haematoma enclosing the injury site and initiating angiogenic activity. Inflammatory 
cells, fibroblasts and stem cells are then recruited to the injury site and new blood 
vessels are formed from the expansion of the pre-existing vessels. Soluble molecules, 
such as growth factors and cytokines, are released at this stage in order to encourage 
and regulate the re-growth of the bone (Carano and Filvaroff, 2003). 
Granulation tissue eventually forms at the end of the fractured bone and is gradually 
replaced by fibrocartilage. The internal callus of this fibrocartilage proceeds through 
the process of endochondral ossification and becomes mineralised by calcium 
phosphate, in the form of hydroxyapatite crystals, to form a woven bone callus, while 
the external callus undergoes intramembranous ossification to form a periosteum. This 
repair gives rise to a large callus which needs to be remodelled. The callus is reduced in 
size as the woven bone undergoes remodelling and is replaced with secondary lamellar 
PhD Thesis                                                                                                               Bardsley 2014 
12 
 
bone. The vascular supply also is remodelled to be appropriate for the final bone tissue 
(Trueta, 1963, Carano and Filvaroff, 2003). 
This process of natural bone repair can only occur within a bone defect or fracture 
which is less than 2-2.5 times the diameter of the bone (critical sized for bone repair), 
where the fractured surfaces are close together (Reichert et al., 2009, Gugala et al., 
2007). Critical size defects in the bone are defects which will not repair within the 
animal’s lifetime and become scarred rather than being regenerated leading to non-
union (Petite et al., 2000), which seriously affects the quality of life of the patients due 
to the associated loss of function (Drosse et al., 2008). It is therefore necessary to 
investigate the use of a bone graft material in order to allow or aid the healing of these 
defects. 
2.3 Clinical Bone Defect Repair 
Healing complex bone defects, which will not heal naturally, can be achieved either 
through bone transplants or by the insertion of a tissue-engineered graft. Any material 
used to fill these defects should ideally be osteoconductive and osteoinductive. 
Osteoconductive materials provide a scaffold which promotes the growth of bone on 
the graft material, whereas osteoinductive materials stimulate bone precursor cells to 
progress down the bone-forming cell lineage (Albrektsson and Johansson, 2001). 
2.3.1 Current Approaches for Bone Grafts 
The most commonly used method in repairing critical bone defects is by transplanting 
a bone graft into the defect. Bone grafts are required to fill a void and support and 
enhance biological regeneration and are classified as: 1) autologous, where the bone is 
harvested from the patient with the defect; 2) allogeneic, where bone is harvested 
from another person or cadaver or 3) xenogeneic, where bone is harvested from an 
animal source (Parikh, 2002). A more recent approach is to use a biomaterial to fill the 
defect and encourage bone growth. The type of graft material used is dependent on 
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several factors including: the clinical application; defect size and the volume of bone 
required; the desired bioactivity and resorption rates; side effects and the availability 
and cost of the graft (Brydone et al., 2010). All current clinical methods have different 
activities and strengths (Table 2-2), which affect their ability to aid bone tissue 
regeneration in vivo. 
Table 2-2: The different properties of current bone graft techniques, showing their 
structural strength and osteoconductive and osteoinductive nature (adapted from 
Brydone et al. (Brydone et al., 2010)).  
Graft Type Strength Osteoconductivity Osteoinductivity 
Autografts    
Cancellous + ++ + 
Cortical ++ + +/- 
Allografts    
Cancellous + ++ + 
Cortical ++ +/- +/- 
Demineralised bone matrix - ++ +++ 
Bone Substitutes    
Calcium phosphates - + - 
Bioactive Composites + + - 
 
Autologous transplantation (autograft) is seen as the gold standard for bone repair. 
Bone tissue is harvested from the patient, usually from the iliac crest or tibia, resulting 
in a living, osteoconductive and osteoinductive graft. Autografts have been proven to 
allow for efficient repair within the defect in vivo (Frohlich et al., 2008). One advantage 
of autologous grafts is that there is no immune rejection of the graft (Chang et al., 
2009). It is also possible to harvest bone with its vascularisation intact, which can be 
reattached at the site of injury to reduce the chance of tissue necrosis after 
implantation into a low nutrient wound bed.  Autografts, however, do have 
disadvantages. There is a risk of donor site morbidity and prolonged post-operative 
PhD Thesis                                                                                                               Bardsley 2014 
14 
 
pain, which affects around 10-30 % of patients (Meijer et al., 2007, Goulet et al., 1997). 
The volume of bone which can be harvested from the patient is also limited, especially 
in younger patients, and therefore autografts are not suitable when large or multiple 
defects are present without causing instability of the donor bone (Hing, 2004). 
Allografts and xenografts, where bone is taken from a cadaver or animal source 
respectively, have been used to circumvent the issues seen when using autografts. 
There is no donor site morbidity or associated post-operative pain. Allografts also allow 
for higher volumes of bone to be harvested and therefore are useful when looking at 
large or multi-defect repair. Bone allografts, however, are less osteoconductive and 
osteoinductive than autologous bone grafts due to the high degree of processing 
required to reduce immunogenicity and ensure sterility of the allografts. This leads to 
slower rates of revascularisation and a higher rate of graft re-absorption (Frohlich et 
al., 2008). Allografts also have the potential disadvantage to cause immunogenic 
responses and possible viral transmission between patients (Damien and Parsons, 
1991, Chang et al., 2009). One study using allografts for bone regeneration after bone 
tumour resection showed a 19 % chance of fracture, 14 % non-union and a 10% chance 
of infection (Mankin et al., 1992).  
The use of biomaterials to repair defects is a relatively new field and some of the bone 
substitutes used for clinical applications are shown in  
Table 2-3. Calcium phosphates are commonly used as biomaterials for bone repair due 
to their osteogenic potential and biocompatibility and have been researched for their 
ability to repair bone defects since the 1920s (Albee, 1920, Ogose et al., 2005). While 
hydroxyapatite is the main component in bone and has a high compressive strength, it 
is a brittle material which has low rates of resorption (Stevens, 2008). A biomaterial 
should in general degrade in vivo at the same rate at which cells within the body 
deposit new ECM. Tri-calcium phosphate, therefore, is often used as an alternative to 
hydroxyapatite, as although it is not as strong it has faster resorption rates which are 
more comparable with the rate of ECM deposition (Ogose et al., 2005). The use of a 
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biphasic calcium phosphate (usually a mixture of hydroxyapatite and tri-calcium 
phosphate), is seen to be advantageous, as this biomaterial is a balance between 
strength, from the hydroxyapatite, and higher resorption rates, from tri-calcium 
phosphate. Biphasic calcium phosphates are used in many of the biomaterials used for 
bone regeneration. The use of calcium phosphates, however, do have drawbacks as 
these materials can be prone to fatigue, fracture, toxicity and wear (Chang et al., 2009).  
Bioactive composites, where there is a combination of polymer and calcium phosphate, 
have also been used in the repair of defects. The majority of these biomaterials utilise 
collagen as the polymer, as this is one of the main ECM components within bone itself 
and is a haemostatic agent as well as aiding bone regeneration (Lawson and 
Czernuszka, 1998). The advantage of these composite scaffolds is that they may be 
able to better simulate the mechanical characteristics of natural bone (compressive 
and tensile strength) (Lickorish et al., 2007). 
Bioactive glass (bioglass) are also used for the repair of defects and are composed of 
SiO2, Na2O, CaO and P2O5 in different proportions. Bioactive glasses have been shown 
to bond with bone more rapidly than other bioactive ceramics (Oonishi et al., 1997, 
Oonishi et al., 2000)  as well as stimulating osteoblasts. This stimulation has been 
attributed to the release of soluble silica and calcium ions from bioglasses after 
implantation. (Xynos et al., 2000). Bioglass 45S5 is the most commonly used 
formulation of bioglass, developed by Hence et al in the late 1960s, and contains 45 wt 
% SiO2 and a 5:1 ratio of CaO to P2O5. Bioglass has been shown to be highly reactive in 
aqueous media and is extremely bioactive, however, it does have disadvantages 
including mechanical weakness, which makes it unable to be used in load-bearing 
applications (Jones, 2013). 
Other methods include the direct injection of growth factors into the site of the defect 
in order to promote new bone regeneration. BMP-2 is the most common growth 
factors used for bone tissue engineering and is approved for use in the treatment of 
bone defects by the FDA. BMP-2 is a member of the transforming growth factor b 
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super family and has been shown to promote the osteogenesis of MSCs  and result in 
bone formation both in vitro and in vivo (Zhang et al., 2014). While this method has 
been shown to be clinically effective it needs to be implanted with a carrier, such as 
collagen sponges, to prevent immediate diffusion from the injury site due to its short 
half-life (7-15 minutes) (Friess et al., 1999). This short half-life means that 
supraphysical concentrations of BMP-2 are required, which can cause complications 
and side effects,  such as osteolysis, ectopic bone formation and radiculitis (Carragee et 
al., 2011). 
Table 2-3: Current biomaterials approved for clinical use for the repair of large or 
complex bone tissue defects. 
Product Name Company Composition Form 
Norian®SRS® DePuy Synthes Calcium phosphate 
 Paste 
 Putty 
Conduit® TCP DePuy Synthes β-tricalcium phosphate  Granules 
ChronOS® DePuy Synthes β-tricalcium phosphate 
 Granules 




















phosphate and collagen 
 Compression 
resistant blocks 
Vitoss® Stryker Biotech 
 β-tricalcium phosphate 
and collagen 
 Putty 
 preform shapes 
NovaBone NovaBone 45S5 Bioglass 
 Particles (90-
710μm) 
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2.4 Current Tissue-Engineering Approaches to Bone Transplants 
The clinical approaches to bone regeneration discussed in section 2.3.1, have the 
ability to repair bone defects, however, they all have their disadvantages. Regenerative 
medicine and in particular tissue-engineering of a bone graft, therefore, would be 
advantageous as it allows a natural tissue to be produced that will enable complete 
bone healing which has fewer side-effects to the patient, as well as overcoming 
problems with material quality and abundance.  
Regenerative medicine can be defined as a method which “replaces or regenerates 
human cells, tissues or organs, to restore or establish normal functions.” (Mason and 
Dunnill, 2008) Tissue-engineering is found within this field and is an 
“interdisciplinary field that applies the principles of engineering and life sciences 
toward the development of biological substitutes that restore maintain, or 
improve tissue function or a whole organ." (Langer and Vacanti, 1993). The work 
presented within this thesis aims to tissue engineer a hypertrophic cartilage which can 
be used to regenerate bone within complex defects.  The area of tissue engineering is 
quickly evolving to include more novel approaches using a combination of scaffolds, 
cells and growth factors (Tuan et al., 2003), to allow for tailor-made bone grafts which 
will enable the repair of the damaged bone. Table 2-4 shows examples of in vivo 
experiments using tissue-engineering approaches using either growth factors, cells or 
both and a scaffold to induce bone repair in critical defects. 
The most common approach in tissue-engineering is to utilise a scaffold to support 
cells in vitro while they create an extracellular matrix, which will provide a foundation 
for the formation of a new native tissue (Howard et al., 2008). This approach has been 
utilised for bone tissue-engineering as shown in Table 2-4. The majority of this work 
revolves around using adult stem cells, MSCs and growing these cells on scaffolds 
including porous ceramics, such as hydroxyapatite (Bruder et al., 1998), and polymers, 
such as PGLA (El-Amin et al., 2002), to produce bone through induction of osteoblastic 
differentiation followed by ECM formation. The bulk of this research has focussed on 
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following the pathway of intramembranous ossification to produce a bone tissue; 
however this method of tissue-engineering has drawbacks as bone requires a high 
nutrient exchange and high vascularisation which is not present within the wound bed 
(Hing, 2004).  
There are several clinical studies utilising regenerative medicine for the regeneration of 
bone in non-union defects. The majority of these studies utilise MSC derived from the 
patient and a calcium phosphate scaffold material (Table 2-5). The advantages of these 
materials is that the use of both MSC and calcium phosphates have been approved for 
use individually (Chatterjea et al., 2010). The majority of clinical studies have focused 
on the addition of undifferentiated MSC directly on to the scaffold before direct 
implantation into the defect without in vitro differentiation. This thesis differs from the 
current in human clinical studies and aims to fabricate a fully engineered tissue which 
is both osteoconductive and osteoinductive, which will give equivalent or better 
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Table 2-4: Examples of current bone tissue-engineering approaches for in vivo bone 
healing 
Cell Source Scaffold material Species Details Reference 
None rhTGF-β and rhBMP-2 
calcium phosphate 
Rabbit  Orthopic bone formed in 
cranial defects compared to 










 Compared to scaffold 
without VEGF 
 After 4 weeks enhanced 










 Critical size defects (4mm) 
 Defects engrafted with 
undifferentiated adipose-
derived stem cells showed 
bone regeneration 
throughout  
(Levi et al., 
2010) 
MSCs Triphasic ceramic 
coated HA 
Goat  20mm bone defect 







Cross-linked Collagen Rat  7mm cranial defects in 
Wistar rats 
 Both cell-free and MSC grafts 
showed excellent healing 
compared to the empty 
defect.   
(Lyons et 
al., 2010) 
MSCs PLGA Rabbit  in vitro bone formation 
before implantation into 
mandibular 
 After 12 weeks polymer had 
degraded and defect was 
filled with bone 








 Placed subcutaneously in 
nude mice 
 8weeks post in vivo 
implantation new bone had 
formed on the composite 
scaffold  
(Kim et al., 
2008) 
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Table 2-5: Examples of in human clinical studies looking for the regeneration of bone in 










3 (long bone 
defects) 
 First clinical trial in 
humans using hMSCs 
 Good clinical recovery 
with bone regeneration 
and integration of the 
host bone with no side 









 5 patients had no new 
bone formation and 
highlighted the variation 










  First clinical study to 
use autologous MSCs 
derived from adipose 
tissue and expanded. 
 Use of rhBMP-2  
 Use of a microvascular 
flap  
 8-month follow up 
indicated presence of 
mature bone.  
(Mesimaki 
et al., 2009) 
2.5 Tissue-Engineering Bone using the Endochondral Ossification 
Pathway 
Most bone tissue-engineering research, as discussed in previous sections, has centred 
on the direct differentiation of stem cells into osteoblasts to produce bone tissue and 
therefore mimics the intramembranous ossification pathway. This differentiation 
technique, however, has several drawbacks for clinical applications. Osteoblasts and 
bone tissue require high nutrient exchange rates and oxygen levels within the tissue 
and because of these requirements, cannot withstand the hypoxic conditions usually 
found in a wound bed (Malda et al., 2003).  It is therefore, more difficult for these 
PhD Thesis                                                                                                               Bardsley 2014 
21 
 
grafts to survive once implanted into a defect unless a functionally adequate blood 
supply can be immediately established to the tissue. This need for high nutrient 
exchange also limits the size of graft that can survive during in vitro culture as well as 
after in vivo implantation.  
Therefore tissue-engineering a bone graft material following the endochondral 
ossification pathway maybe an advantageous method to circumvent the problems 
seen when using the intramembranous pathway. The production of a hypertrophic 
cartilage template which can be implanted into a defect and be remodelled into bone 
maybe advantageous as cartilage is an avascular tissue that is better able to survive the 
low oxygen tensions found within the wound bed. Early work demonstrated the ability 
of immortalised articular chondrocytes to become hypertrophic and mineralise in 
pellet culture (Oyajobi et al., 1998). There are, however, significant concerns 
associated with the use of genetically modified cells for a clinical application. Scotti et 
al have also demonstrated that MSCs can be directed down a hypertrophic lineage 
producing cell pellets in vitro which express a low level of collagen type X, and after 
extended culture in the absence of TGF-β exhibit a mineralised outer collar. After in 
vivo subcutaneous implantation these grafts were able to be remodelled with the 
cartilage template being reabsorbed and replaced with bone ossicles (Scotti et al., 
2010).  
Work carried out previously in our laboratory demonstrated that chondrocytes isolated 
from the nasal septum and the sternum had the ability to progress down a 
hypertrophic differentiation pathway (Kwarciak, 2009). This was achieved through the 
addition of ascorbic acid (vitamin C) and insulin into the culture medium. Ascorbic acid 
has been shown to be a critical factor in the process of endochondral ossification with 
ascorbic deficiency causing scurvy and an ascorbic acid deficiency in the growth plate 
causes a decreased chondrocyte proliferation, ECM deposition and osteoblast cell 
number (Kipp et al., 1996). In vitro, addition of ascorbic acid has been shown to 
significantly increase alkaline phosphatase activity and collagen type X mRNA levels in 
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chondrocytes (Leboy et al., 1997, Leboy et al., 1989). Insulin is used as an alternative to 
insulin growth factor (IGF) as it has the ability to bind to both insulin receptors and IGF-
1 receptors (Ballock and Reddi, 1994). Insulin causes the morphological increase in the 
cellular volume of the chondrocytes as well as being mitogenic to chondrocytes 
(Bohme et al., 1992a). The use of these nasal and sternum chondrocytes resulted in 
hypertrophic tissue-engineered grafts, which not only had a large cellular morphology 
but also expressed high levels of alkaline phosphatase and collagen type X. No 
mineralization of these grafts was detected in vitro using the conditions above 
(Kwarciak, 2009).  
Previous research has shown that undifferentiated hyaline chondrocytes will not form 
new bone when placed into a bone defect (Vacanti, 1995). However, initial work 
illustrated that tissue engineered hyaline chondrocyte constructs, differentiated down 
a hypertrophic cartilage phenotype, can produce a mineralised cartilage matrix after in 
vivo subcutaneous implantation (Kwarciak, 2009). Stringer et al also demonstrated that 
cells derived from 8-9 week human embryonic femurs produced osteoinductive signals 
for the regeneration of vascularised bone in vivo (Stringer et al., 2007). Therefore, the 
potential of hypertrophic cartilage grafts to be remodelled into bone tissue once 
placed within a bone defect needs to be further investigated. 
2.5.1  Cells for Bone Tissue-Engineering  
The advantage of using live and metabolically active cells for tissue-engineering bone is 
that they can provide the appropriate tissue ECM required to initiate repair. The cell 
source used for tissue-engineering should be available in high enough numbers, not 
cause immune-rejection of the graft nor have tumourgenetic potential.  It is important 
for bone tissue-engineering that the chosen cell source has osteogenic potential, 
and/or is capable of producing a matrix with osteogenic potential.  
The majority of previous work in bone tissue-engineering research is currently centred 
on the use of stem cells and their differentiation down an osteogenic pathway to 
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recapitulate intramembranous ossification. Adult stem cells have previously been used 
in bone tissue-engineering as they are isolated from mature tissues and enable the 
harvesting of an autologous stem cell source while circumventing both the ethical 
objections and potential immune responses seen with embryonic stem cells (ESC). 
Adult stem cells however, unlike ESC are multipotent rather than pluripotent in their 
differentiation capacity and therefore, the appropriate stem cell source is required to 
ensure that the isolated cells have sufficient capacity to fully differentiate down an 
osteogenic lineage. Commonly used adult stem cells are bone marrow-derived 
mesenchymal stem cells (BM-MSCs) and adipose-derived mesenchymal stem cells 
(ASC). 
ASC were first derived by Zuk et al. in 2001 and have been shown to have osteogenic 
and chondrogenic potential (Zuk et al., 2002). In published data, however, there is 
variation in the consistency of ASC to differentiate down particular pathways, while De 
Ugarte et al and Hattori et al showed no difference between the osteogenic and 
chondrogenic differentiation of ASC and BM-MSCs, Im et al and Mehlhoen et al 
observed a lower osteogenic and chondrogenic potential of ASC (De Ugarte et al., 
2003, Im et al., 2005, Hattori et al., 2004, Mehlhorn et al., 2006).  
BM-MSCs are the most commonly sourced adult stem cells for bone tissue-engineering 
due to their known ability to directly differentiate into bone precursors, osteoblasts. 
These cells are available in fewer numbers and their isolation is more invasive than 
ASC, however their differentiation protocol is well established and bone marrow 
aspirates have been approved for medical use. BM-MSCs have also previously been 
shown by Scotti et al to differentiate to produce the markers of hypertrophic 
differentiation. 
However, the use of adult stem cells still has drawbacks. BM-MSCs are commonly 
isolated from a bone marrow biopsy from the iliac crest. This procedure is invasive and 
can cause post-operative pain for up to 2 years after the bone marrow has been 
harvested. Also, adult stem cells have not produced high levels of ECM on 
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differentiation when cultured in a three-dimensional (3D) environment. This restraint, 
limits the size of a tissue graft which can be produced in vitro for implantation into a 
defect site. 
An alternative to adult stem cells is to find a cell source which is able to undergo 
hypertrophic differentiation and produce a high level of appropriate ECM. Two such 
cell sources have been identified by previous work by A Kwarciack, the nasal septum 
cartilage and rib cartilage (Kwarciak, 2009). Both of these cartilage sources have been 
shown to differentiate down a hypertrophic lineage, producing cells with a large 
cellular morphology and expressing the hypertrophic markers collagen type X and 
alkaline phosphatase. The use of chondrocytes harvested from the nasal septum 
cartilage is advantageous as these cells are easily accessible for harvesting clinically and 
therefore, the donor site is less likely to be subject to tissue morbidity or pain. Nasal 
chondrocytes are also highly proliferative and this proliferation capacity is not related 
to the patient’s age. This high proliferation potential should permit the biopsy size to 
be kept relatively small. Therefore the use of nasal septum chondrocytes is potentially 
more advantageous than the use of BM-MSCs, due to the high amount of ECM 
produced, the ease of isolation and the ability to differentiate down a hypertrophic 
cartilage phenotype. 
2.5.2  Scaffolds for Bone Tissue-Engineering  
While the majority of research in this area uses pellet cultures as a 3-dimensional (3D) 
environment for the cells, it is necessary to look at the use of scaffolds in order to 
produce larger grafts to create a fully functional graft tissue and for repair of critically 
sized defects. A major function of a scaffold is that of a 3D supporting structure in 
appropriate shape/templates for cell proliferation, ECM deposition and tissue 
regeneration. Ideally a scaffold for tissue regeneration should be:- (a) biocompatible, 
promoting cell adhesion and proliferation; (b) biodegradable (ideally with the rate of 
scaffold degradation occurring at the same rate as that of new tissue formation); (c) 
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representative of the physical and mechanical properties of the target tissue (Rahaman 
et al., 2011). While the physical properties of the scaffold are important when directly 
implanting into load-bearing sites the method used in this thesis is to use the scaffold 
to produce a hypertrophic tissue in vitro before implantation into a defect site, 
therefore the physical and mechanical properties of the scaffold are not as vital in this 
research, as it is hoped that the new tissue will take on the required properties. 
Previous research in bone tissue-engineering has utilised ceramics, polymers and 
ceramic/polymer composites as scaffolds to repair bone defects (Refer Table 2-4); 
however as we are looking to create a hypertrophic cartilage it is also important to look 
at scaffolds used for cartilage tissue engineering. 
Cell attachment to scaffolds is affected by the adsorption of proteins on to 
biomaterials. These proteins contain integrins such as RGD (Arg-Gly-Asp), which are 
essential structures recognised by the transmembrane integrin receptors of the cells. 
These receptors then form localised focal adhesions which adhere the cells to the 
biomaterials. This integrin binding can then activate a signalling cascade, which will 
alter gene and protein expression of the cells (Stevens and George, 2005). Therefore 
the ability for proteins to adsorb on to biomaterials is essential in cell attachment, 
survival and differentiation. When biomaterials come into contact with serum based 
media spontaneous, non-specific adsorption of soluble ECM proteins occurs. ECM 
proteins adsorb with a wide range of orientations and 3D conformations dependent on 
the characteristics of the biomaterial, including topography, chemical composition and 
hydrophobicity (Wang et al., 2012). For example highly hydrophobic biomaterials 
thermodynamically bind proteins which may cause denaturation and a decrease in 
bioactivity, however, highly hydrophilic biomaterials expel proteins from the 
surrounding area and inhibit adsorption (Wilson et al., 2005). It is therefore essential 
that any biomaterial used for tissue-engineering is able to support the adsorption of 
proteins and consequently cell attachment. 
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Calcium phosphate-based ceramics, such as hydroxyapatite, have been used as bone 
substitutes for around 40 years and most research using scaffolds for bone tissue-
engineering has centred on the use of these substrates. This interest is because the 
inorganic component of natural bone is 85-90 % calcium phosphate, with the mineral 
present as hydroxyapatite crystals (HA) (Lichte et al., 2011). Calcium phosphates are 
also known to be biocompatible (Hutmacher et al., 2007) and while they are not 
osteoinductive, the release of Ca2+ and PO4
3- ions from these materials permits them to 
bind to bone and allow new tissue formation (Lichte et al., 2011). Calcium phosphates 
have also been shown to allow for protein absorption and subsequent cell attachment, 
migration and differentiation (Wang et al., 2012). The optimum pore size for 
osteogenic differentiation has been shown to be around 300-500 µm (Kuhne et al., 
1994). However while this pore size allows good nutrient exchange, as the porosity of 
the ceramic increases the material become more brittle (Stevens, 2008). Therefore, 
while calcium phosphate ceramics may have a similar compressive strength and 
composition to natural bone, their brittleness and low tensile strength seen at the 
required porosity for bone tissue regeneration makes these ceramics difficult to use in 
a clinical application due to their potential predisposition to fracture. The use of 
synthetic hydroxyapatite is common as it has a chemical composition which is similar 
to bone, as well as being non-toxic and not causing an immune response (Silva et al., 
2005). Other calcium phosphates such as brushite are used in bone cements and have 
been found to be non-toxic and able to bind well to natural bone. Brushite also has the 
advantage of being remodelled into hydroxyapatite in vivo. While calcium phosphates 
are often used for bone tissue engineering they are not used for cartilage tissue 
engineering. Calcium phosphates are however often incorporated into the 
osteochondral constructs where two scaffold layers are utilised, calcium phosphate for 
the subchondral bone and a polymer based scaffold for the cartilage element of the 
tissue engineered construct (Martin et al., 2007). 
Polymeric scaffolds have also been used for both bone and cartilage tissue-
engineering, and both naturally occurring and synthetic polymers have been used. 
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However, due to their low elastic modulus, loading of these materials leads to plastic 
deformation and a reduction in scaffold porosity therefore, they are not ideal for load 
bearing sites (Lichte et al., 2011, Gorna and Gogolewski, 2006).  
Naturally occurring polymers such as collagen, gelatin and fibrin, been utilised for bone 
and cartilage tissue engineering. These protein-based polymers are found in the 
extracellular matrix of tissues and have the advantage that they have the potential to 
direct cellular migration, growth and organisation during the process of tissue 
regeneration. Naturally occurring polymers may cause immunogenic responses and 
there is less control over mechanical and biodegradable properties. There is also an 
issue with batch to batch variation and a limited supply leads to them being costly. (Lui 
et al., 2003). Synthetic polymers are advantageous as they can be fabricated to be 
biocompatible, degradable and easy to process, making them good candidates for 
scaffold fabrication for 3D cell culture. There may, however, be issues with cell 
attachment and growth when using this polymers. Polyesters, such as polyglycolic acid 
(PGA) and poly(co-lactic) acid (PLLA), have been well researched for tissue-engineering 
as they have Food and Drug Administration (FDA) approval for other medical uses 
(Ueda and Tabata, 2003). Although the rates of degradation of these polyesters can be 
controlled, during their “bulk” degradation they do release lactic and glycolic acid by-
products which can cause inflammation and necrosis of nearby tissues (Shoichet, 
2010). These polyesters have been used successfully for the formation of both tissue-
engineered bone and cartilage grafts (Table 2-4). Cell attachment on to polymeric 
biomaterials is variable and dependent on the polymer used. Natural polymers have 
the advantage of being composed of proteins which contain integrins for cell 
attachment and therefore it is not dependent on protein adsorption. Synthetic 
polymers, however, do not have proteins and integrins on their surface and therefore 
cell adhesion to the scaffold is reliant on protein adsorption to the surface of the 
biomaterial. Polyesters, PGA and PLLA, have both been shown to allow for protein 
adsorption and subsequent cell attachment without the need for surface modification 
(Atthoff and Hilborn, 2007).  
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To overcome the lack of mechanical stability seen with polymers and the brittle nature 
of ceramics at the required porosity, composite scaffolds have been investigated. The 
rationale for utilising a composite scaffold of polymer and ceramic is that alone, 
neither of the materials above mimics the physio-chemical properties of natural 
trabecular bone. It is therefore hoped that by fabricating composites of  polymers and 
ceramics will allow for the advantages of both materials to be harnessed (Lickorish et 
al., 2007). For example, the ceramic component will increase the mechanical strength 
and osteoconductive nature of the scaffold whereas the polymer component enables 
the fabrication of a porous non-brittle scaffold which can be biodegradable. Most work 
in the area of composite scaffolds has revolved around the incorporation of 
hydroxyapatite within the polymer, through electrospinning (Kim et al., 2006, Deng et 
al., 2007).  Therefore the cells will not experience the hydroxyapatite until the polymer 
degrades and exposes the mineral. Therefore, a method of surface precipitation and 
modification of a scaffold material may have more of an impact on the cells cultured in 
it and highlight the osteoconductive nature of the hydroxyapatite. 
In this research we are looking to create a hypertrophic cartilage, which will mineralise 
into bone. It is therefore, essential that the scaffold material is able to support both 
cartilage and bone. Due to this synthetic polymer scaffolds were chosen as a basis for 
this research as they have been used for the tissue-engineering of both tissues. 
Synthetic polymer scaffolds can be fabricated in several different ways, including 
textile methods, particulate leaching, melt moulding, electrospinning and 3D printing. 
All of these fabrication methods produce scaffolds with different structures and 
surface topography (Liu and Ma, 2004). When tissue-engineering it is important that 
the scaffolds are porous and allow for nutrient exchange and the build-up of 
extracellular matrix. Particule leaching, 3D printing and melt moulding produce 
micropore structures, whereas textile methods and electrospinning produce fibrous 
scaffolds, with either micro or nanofibers (Stevens and George, 2005). In this thesis we 
will focus on fibrous scaffolds produce using textile methods and electrospinning. The 
PGA scaffold material is a non-woven needle-punched PGA scaffold purchased from 
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Cellon. This method produces a highly porous microfiber scaffold material with a high 
surface area. Electrospinning will also produce a fibrous scaffold with a more mat like 
structure. Electrospinning was first used in the 1930s for industrial applications and has 
recently evolved to process polymers with both micro- and nano- fibers for tissue 
engineering applications. Electrospun scaffolds are produced by forcing a 
polymer/solvent solution through a capillary under a high voltage onto a grounded 
collection target. As the jet travels through the air the solvent evapourates depositing a 
non woven polymer fabric on the collection target (Ma. 2004). 
The scaffolds produced by Cellon have a micrometer fibre diameter, however, different 
fibre diameters have been shown to have different effects on cell attachment, 
migration and differentiation. When looking at the ECM the fibrous structures of 
collagen and other ECM proteins have a nanoscale topography, it has therefore been 
suggested that a nanofiber diameter maybe best suited for mimicking the natural 
environment of the cells in vitro (Stevens and George, 2005). In this thesis, however, 
we have decided to utilise microfiber scaffolds as hypertrophic chondrocytes have a 
large micrometer morphology and therefore should respond to the microfiber 
topography of the scaffolds.  
2.5.3 Decellularised Extracellular Matrix as a Scaffold for Bone Tissue-
Engineering  
The ECM is unique and specific to the cell type and function of the tissue. The presence 
and composition of the ECM is also important for tissue and cell survival and for cell-
growth factor and cell-matrix. The ECM is composed of a complex mixture of proteins 
which have both structural roles (e.g. collagens), and functional roles, (such as growth 
factors), in the tissue (Badylak et al., 2009). ECM provides the ideal topographic signals 
for tissue regeneration and it also acts as a store of bioactive factors such as growth 
factors. In addition, the ECM can modulate the interaction of various growth factors 
with the cell surface. Therefore, the interaction between the cells and the ECM is 
important in both the maintenance of the tissues and the migration and differentiation 
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of cells within the tissue (Badylak, 2002). For these reasons, the use of an ECM scaffold 
material has some advantageous over the use of manufactured, synthetic graft 
materials. The  3D environment has been shown to have a large effect on cell 
behaviour, attachment and migration as well as allowing for constructive remodelling, 
producing a high quality tissue with optimal functionality (Benders et al., 2013). 
Currently, decellularised matrices are being investigated for the regeneration of several 
tissues including heart valves (Kasimir et al., 2003, Rieder et al., 2004), trachea 
(Remlinger et al., 2010), muscle (Borschel et al., 2004) and abdominal tissues such as 
bladder and small intestine (Chen et al., 1999). The use of a decellularised ECM as a 
scaffold material is currently employed in the clinic in the form of a bone allograft. For 
these bone graft materials, in which is the bone is either taken from a cadaver or 
xenogeneic source. However, before in vivo use, allograft bone grafts require a high 
level of tissue processing to ensure effective removal of all cellular material to prevent 
an immune reaction to the graft material. However, many of the bioactive factors 
stored in the bone are removed during the tissue processing. Therefore, the capacity of 
allogeneic bone grafts to regenerate bone is reduced compared to that of an 
autologous bone graft. 
When developing a decellularised graft it is important that the cellular content is 
removed in order to modulate the macrophage mediated immune response in vivo. 
However, there are currently no set guidelines for the amount of cellular material 
which must be removed from the tissue to prevent an immune reaction. It is also 
important that the architecture and topography of the ECM is minimally altered and 
that ECM proteins are not removed from the tissue during the decellularisation process  
as these are essential in enabling cellular migration, invasion and stimulating tissue 
formation . The biomechanical properties of a tissue should also not be altered by the 
decellularising process the tissue as these properties also have a large effect on the cell 
differentiation and migration within the tissue (Benders et al., 2013).  
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While the use of decellularised ECM of organs and tissues isolated from the human 
body are advantageous as they have a better microstructure and biomechanical 
properties, the availability of tissues for harvest is low (Hoshiba et al., 2010). This is 
especially the case when looking for hypertrophic tissue which is only present in the 
growth plate of the young and adolescent. Therefore, approaches for culturing cells in 
an appropriate 3D environment to produce an ECM in vitro which can then be 
decellularised has been utilised since the 1970s where ECM from fibroblasts was 
successfully decellularised by both Chen et al and Hedman et al (Chen et al., 1978, 
Hedman et al., 1979).  
Therefore, it is suggested that a decellularised hypertrophic cartilage may be able to 
act as a bone graft substitute to stimulate bone formation in vivo, as it will contain all 
the cues required for angiogenesis and bone remodelling. As discussed in Section 2.1.4 
hypertrophic chondrocytes undergo apoptosis once terminally differentiated. Hence, 
these cells may have a limited direct role in the subsequent bone formation, once the 
ECM of the hypertrophic cartilage contains the appropriate bioactive factors to initiate 
angiogenesis and to attract osteoclast and osteoblast progenitors to initiate the 
cartilage remodelling into bone.  Therefore, it is therefore that if a decellularised 
hypertrophic cartilage were used as a bone graft substitute, the ECM is not disrupted 
and that the growth factors are not removed from the graft during the 
decellularisation process.  
When looking at current decellularisation methods it is essential that a method is 
chosen which removes the majority of the cellular material without disrupting the 
ECM. Physical methods, such as repeated freeze-thawing of the tissue, are effective at 
cell lysis and cause little disruption in ultra-structure or the mechanical properties of 
the tissue. Hypotonic solutions can also be used as they lyse cells through simple 
osmotic effects without affecting the ECM. The use of detergents, such as sodium 
dodecyl sulphate (SDS), can have deleterious effects on the ECM which increase with 
exposure time to the detergent. However, detergents can be excellent decellularising 
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agents as they dissolve cell membranes and dissociate cellular DNA from the histone 
proteins. Therefore detergents should be used at low concentrations for short periods 
of time in order to minimise ECM disruption. Chelating agents, such as 
ethylenediaminetetraacetic acid (EDTA), are important for dissociating the cells from 
the ECM proteins, but can cause subtle protein-protein interaction disruptions. 
Peracetic acid is often used as a disinfecting agent and to remove residual nucleic acid 
from the tissue with a minimal effect to the ECM. It is therefore essential to pick the 
correct decellularisation protocol to optimise the removal of cellular content while 
minimising ECM disruption (Gilbert et al., 2006).      
2.5.4 Culture Conditions for Bone Tissue-Engineering 
The culture conditions used when culturing tissue engineered tissues are important for 
appropriate cell differentiation, ECM production and tissue survival.  
Static cultures are typically used to culture cells as cell pellet. However, mass transport 
of oxygen and soluble nutrients and exchange of waste products can become a 
problem if the cell pellets become too large. Cell pellets larger than 1 mm in diameter 
can exhibit a necrotic core caused by hypoxia and a lack of nutrient exchange 
(Sutherland et al., 1986). Static culture conditions have also been shown to have a 
detrimental effect of the production of glycosaminoglycans (GAG) within the ECM of 
chondrocyte pellet cultures as well as those cultured on PGA (Martin et al., 1999). 
Hirao et al showed that hypoxia inhibits terminal (hypertrophic) differentiation through 
the activation of the smad pathway keeping the chondrocytes in a hyaline phenotype 
(Hirao et al., 2006). Therefore when investigating hypertrophic differentiation it is 
important that the chondrocytes do not experience hypoxia in vitro as this will inhibit 
the hypertrophic differentiation of the chondrocytes.  
The mass transport issue can be resolved by adding a dimension of flow of culture 
medium into the culture system; thereby simulating the transport of nutrients to the 
centre of the 3D cultured tissue. This mass transfer becomes more essential as the 
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chondrocytes produce ECM which blocks the pores of the scaffold. Fluid flow has also 
been shown to have a positive effect on the amount of GAG deposited within the ECM 
as it increases intracellular signalling which in turn increases cellular proliferation and 
ECM production (Yellowley et al., 1997). Mild shear stress accelerates endochondral 
ossification by leading to an increase in collagen type X and runx2 expression (Gawlitta 
et al., 2010, Wong et al., 2003) during hypertrophic differentiation. Therefore, it is 
important that both flow and mild shear stress are present within the culture system 
not only to aid nutrient transfer but also to support the differentiation and ECM 
production by the chondrocytes. The fluid flow, however, should not result in high 
shear within the culture system as this will result in cellular damage and may affect 
chondrocyte attachment on to the scaffold material. 
Fluid flow can be added to a tissue culture system by simply placing the culture vessel 
containing the 3D constructs onto an orbital shaker plate set at low speed. This culture 
conditions are referred to as “semi-static conditions”. However, the fluid flow in these 
systems is difficult to model and therefore, the amount of shear and eddies present in 
this system is unknown. Bioreactors are designed to produce fluid flow in a tissue 
culture system. Therefore, bioreactors have the ability to produce controllable flow 
dynamics allowing for external mass transport and shear stress within the system.  
Several bioreactor types have previously been utilised for the 3D culture of 
chondrocytes, such as wavy-walled bioreactors (Bueno et al., 2005), rotating wall 
vessels (RWV) (Vunjak-Novakovic et al., 1999) and perfusion bioreactors (Davisson et 
al., 2002). All of these bioreactors produce low shear and enable high chondrocyte 
proliferation and GAG accumulation within the ECM. However while these reactors 
have been used for the production of articular cartilage, little research exists using 
bioreactors for the production of a hypertrophic chondrocyte graft.  
Bioreactors are advantageous for the production of tissue in vitro for both research 
and clinical applications of tissue-engineered tissues. The use of bioreactors enables 
the standardisation of cultures and limit operator variability during the in vitro culture 
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periods resulting in more reproducible tissue production. This will be essential when 
looking for regulatory approval for future tissue-engineered therapies. Another 
hindrance to the success of tissue-engineering for clinical applications is the cost of the 
production of tissue grafts. The use of a bioreactor and the automation of the in vitro 
production may lead to a decrease in costs of production of tissue grafts.   
2.5.5 Development of Serum-Free Culture Conditions for Bone Tissue-
Engineering  
Foetal calf serum (FCS) has become an key addition to in vitro cell culture media as it 
supplies a cocktail of serum proteins, including growth factors, hormones, enzymes, 
vitamins and trace elements, which are essential for cell attachment, function and 
survival (Brunner et al., 2010). However the addition of FCS does have drawbacks when 
producing a product for clinical use. FCS is derived from animals and therefore, there is 
a risk of viral transmission through the cultures and into the tissue grafts. FCS is also 
highly variable between batches as different animals produce different levels of growth 
factors and hormones. This variability could have a detrimental effect on cell 
proliferation and differentiation. Culture systems which use FCS will also encounter 
problems when trying to obtain regulatory approval for use within the clinic due to its 
highly variable and undefined nature. Therefore, when considering the production of  a 
hypertrophic cellular graft it is vital that a defined media is used with the ability to 
reproducibly yield the same amount of cellular proliferation and differentiation pattern 
of the cells. 
Hypertrophic chondrocytes have previously been cultured and maintained in serum-
free media, where additions of specific bioactive factors have been made to 
compensate for the lack of FCS. It is important that FCS proteins which are required for 
cell attachment, proliferation and differentiation are substituted into the serum-free 
media so as not to affect cell cultures, while making the media more defined.  
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Bohme et al showed that insulin or insulin-like growth factor (IGF) is required for the 
proliferation of chondrocytes (Bohme et al., 1992a). In 1982 Burch and Lebovitz 
observed that the addition of thyroxine induced both the growth and maturation of 
embryonic chick cartilage in vitro (Burch and Lebovitz, 1983). More recently both 
thyroxine and triiodothyronine have been shown to be a strong initiators of 
chondrocyte hypertrophy when present at a concentration similar to that found in 
plasma and can create linearly organised chondrocytes while increasing the production 
of collagen type X and alkaline phosphatase in serum-free conditions (Bohme et al., 
1992b, Ballock and Reddi, 1994, Robson et al., 2000, Okubo and Reddi, 2003, Bohme et 
al., 1992a).  
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3 Aims and Objectives 
As discussed in Section 2, the healing of non-union fractures and large bone defects 
remains a significant, clinical challenge. Current practices based on the use of 
autologous bone grafts are the most clinically effective, but suffer from well-known 
limitations as described in Section 2.3. Therefore the application of tissue-engineering 
remains an attractive field of research for the regeneration of bone. Bone tissue-
engineering to date has often centred on the direct differentiation of MSCs into 
osteoblasts to form bone following the intramembranous ossification pathway. 
Surprisingly, limited research has been performed on the potential of the 
endochondral ossification pathway and hypertrophic cartilage grafts to overcome the 
limitations of other repair strategies and regenerate bone tissue through the 
differentiation of chondrocytes. The aim of this PhD thesis, therefore, was to 
investigate the feasibility of using the endochondral ossification pathway to form 
hypertrophic cartilage tissue for use as graft materials to repair bone defects. Specific 
objectives were: 
 To investigate the use of electrospinning to produce scaffolds for hypertrophic 
cartilage tissue-engineering and to consider the modification of these scaffolds 
with calcium phosphate in order to produce a composite scaffold with 
enhanced osteogenic potential. 
 To investigate the effect of different batches of foetal calf serum on the ability 
of nasal septum chondrocytes to differentiate down a hypertrophic lineage and 
produce proteoglycans within the extracellular matrix. 
 To reproducibly differentiate chondrocytes down a hypertrophic lineage using a 
range of experimental and commercial scaffold materials, and to examine this 
differentiation using both gene and protein expression. 
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 To investigate the ability of hypertrophic chondrocyte grafts to heal bone 
defects in an in vivo rat model and to compare these results with the use of a 
decellularised graft and a decellularised graft re-seeded with MSCs. 
 To carry out preliminary research into the use of a Quasi-vivo® flow bioreactor 
for the production of hypertrophic chondrocyte grafts. 
 To develop a serum-free media in order to aid with culture standardisation and 
the possible regulatory approval of hypertrophic chondrocyte grafts. 
 
On completion, this research will add substantially to knowledge of hypertrophic 
chondrocyte differentiation and the potential clinical application of hypertrophic 
chondrocyte tissue-engineered grafts as a material or template for bone tissue 
regeneration. 
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4 Materials and Methods 
4.1 Materials  
General tissue culture materials were supplied by Sigma-Aldrich, Poole, UK. Materials 
for RNA work were supplied by life Technologies, UK and immunohistochemical 
analysis materials were supplied by Vector Laboratories, UK. Suppliers of other 
materials are stated within the methods section. 
4.2 Methods 
4.2.1 Scaffold Fabrication and Analysis 
4.2.1.1 Electrospinning 
PLLA (molecular weight 45-69 kDa) was dissolved in 8 % (w/w) in dichloromethane to 
produce a polymer spinning solution. Polymer solution (3 mL) was electrospun at a 
voltage of 16 kV at a rate 3 mL/hour across a distance of 45 cm.  Random fibre 
scaffolds were spun onto a stationary flat metal plate.    
4.2.1.2 Alternate Soaking Protocol 
Electrospun PLLA was treated using an alternative soaking protocol based on the 
method described by Taguchi et al (Taguchi et al., 1999). Scaffolds were soaked in 200 
mM calcium chloride in 1 M Tris-HCl pH 7.4 containing 10 % (v/v) ethanol (Fisher 
Scientific, UK) for 30 seconds, washed in 25 % (v/v) ethanol in distilled water for 30 
seconds, soaked in 120 mM sodium hydrogen phosphate containing 10 % (v/v) ethanol 
for 30 seconds and washed in 25 % (v/v) ethanol for 30 seconds. This protocol was 
repeated for 5 and 10 cycles with the intention of depositing calcium phosphate on and 
between the scaffold fibres. 
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4.2.1.3 Scanning Electron Microscopy  
Scaffolds were attached to scanning electron microscopy (SEM) specimen stubs using 
carbon tabs. Samples were then sputter gold coated using an Edwards Sputter coater 
S150B. Samples were then imaged using Phillips XL20 under a 20 kV beam.  
4.2.1.4 X-Ray Diffraction  
Scaffolds were mounted on glass slides using micropore tape and analysed using the 
Phillips PW1830 set at 40 kV and 30 mA. Scans were performed between 5 ° and 80 ° at 
a rate of 1 o.minute-1 with a step size of 0.05. 
4.2.1.5 Hydrophilic Analysis 
A goniometer was used to analyse the hydrophilicity of the scaffolds by using the 
contact angle method. Scaffolds were placed on the stage and 0.2 mL droplet of 
distilled water was placed on the surface of the scaffold the contact angle between the 
water and the surface of the scaffold was then measured. Figure 4-1 illustrates a 
schematic of a goniometer, showing the contact angle, θ, between the water droplet 









Figure 4-1: Diagrammatic of a goniometer showing the water droplet, the scaffold 
surface and the contact angle, θ  
θ – Contact angle 
Water droplet 
Scaffold surface 
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4.2.2 Cell Culture  
4.2.2.1 Nasal Chondrocyte Isolation 
Nasal cartilage was harvested from the nasal septum of 6 week-old Wistar rats within 2 
hours of slaughter. The cartilage was washed in sterile Ca2+/Mg2+-free phosphate 
buffered saline (PBS) and cut into small sections before being incubated in 2.5 % (w/v) 
trypsin solution for 30 minutes on a shaker plate at 37 °C in a humidified atmosphere 
to remove any remaining endothelial cells from the cartilage tissue. Cartilage tissue 
was then washed in PBS to remove the trypsin and digested for 15 hours in bacterial 
collagenase (3 mg.mL-1, filter sterilised) with 10 % (v/v) FCS (Biosera, UK) in basic 
media: Dulbecco’s modified eagle media (DMEM) supplemented with 100 units.mL-1 
penicillin and 100 µg.mL-1 streptomycin) (PS), 10 mM pH 7.4 Hepes Buffer (Hepes), 1 % 
(v/v) 100x MEM non-essential amino acids (NEAA) and 2 mM L-alanyl-L-glutamine (Glu) 
at 37 °C in a humidified atmosphere. Digested tissue was then passed through a 0.2 μm 
cell strainer (BD Biosciences, Erembodegem, Belgium) to remove any undigested 
cartilage. The isolated chondrocytes were washed in PBS and centrifuged at 1000 rpm 
for 5 minutes to remove the collagenase.  
Chondrocytes were re-suspended in basic media and a cell count was performed using 
a haemocytometer. Chondrocytes were plated out at 2x106 cells per 90 cm cell culture 
dish in 15 mL of expansion media: basic media supplemented with 10 % (v/v) FCS and 
10 ng. mL-1 basic fibroblast growth factor (FGF). Culture dishes were placed in 
incubator, at 37 °C humidified atmosphere of 5 % CO2/95 % air. 
4.2.2.2 Mesenchymal Stem Cell Isolation 
Rat MSCs were isolated from the bone marrow of the femur within 2 hours of the 
animal being slaughtered. Rats were sprayed down with 70 % (v/v) ethanol and 
Trigene® (Scientific Laboratory Supplies, Nottingham, UK) and the femurs removed 
from the hind legs. All soft tissue was removed from the femurs before the ends of the 
bone were removed and 10 mL of expansion media was flushed through the bone 
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cavity and a syringe and syringe needle was used to harvest the bone marrow. The 
bone marrow from each femur was placed in a T25 culture flask and transferred to an 
incubator at 37 °C with a humidified atmosphere of 5 % CO2/95 % air. BM-MSCs were 
allowed to attach to the surface of the culture flask for 24 hours. After 24 hours the 
attached cells were washed with PBS and the BM-MSCs were cultured in expansion 
media.  
4.2.2.3 Cell Expansion 
When cell cultures had reached 80 % confluence, the culture media was removed from 
the cells and the cell monolayers washed twice using sterile PBS. 3 mL of trypsin/EDTA 
(0.05 % (w/v) porcine trypsin and 0.02 % (w/v) EDTA in Ca2+/Mg2+-free Hanks balanced 
salt solution) was added to each culture plate and the cultures were incubated for 3-5 
minutes at 37 °C until the cells had detached from the culture plastic. The detached 
cells were transferred to centrifuge tubes, FCS was added (5 % (v/v) final 
concentration) to inhibit the trypsin and the cell suspension was centrifuged at 1000 
rpm for 5 minutes to pellet the cells. Cell pellets were re-suspended in expansion 
media and a cell count was performed using a haemocytometer. Chondrocytes were 
plated out at 1x106 cells per 9 cm diameter culture dish and MSC were plated out at 
2x106 cells per T75 culture flask. Cells were placed back into the incubator at 37 °C 
humidified atmosphere of 5 % CO2/95 % air. This process was repeated until a 
sufficient number of cells were present the maximum number of passages which cells 
were subject to was 2. 
4.2.2.4 Mesenchymal Stem Cell Lineage Testing  
MSC Adipogenesis 
BM-MSCs were plated out in 6 well plates at a density of 1x106 cells per well and 
cultured until 70 % confluent. The BM-MSCs were cultured in adipogenic induction 
media: basic media supplemented with 1 mg.mL-1 BSA, 10 µg.mL-1 insulin, 1 µM 
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dexamethasone, 100 µM indomethacin and 0.5 mM 3-isobutyl-1 methyl xanthine 
(IBMX) for 72 hours and then cultured for 5 days in basic medium supplemented with 1 
mg.mL-1 BSA and 10 µg.mL-1 insulin. Once differentiated, cells were washed with sterile 
PBS and fixed with 2 % (v/v) gluteraldehyde for 30 minutes at room temperature. Fixed 
cells were then washed twice with sterile PBS and adipogenic differentiation detected 
by incubation of the cells with Oil Red O [3 parts stock solution (0.5  g Oil red O in 100 
mL Isopropanol (Fisher Scientific, UK)) to 2 parts distilled water, filtered] for 2 minutes 
at room temperature. The stain was removed and cells washed five times with distilled 
water before imaging.  
MSC Osteogenesis 
BM-MSCS were plated out in 6 well plate at a density of 1x106 cells per well in basic 
medium supplemented with 1 mg.mL-1 BSA and 10 nM dexamethasone for 24 hours. 
The BM-MSC cultures were then differentiated in osteogenic media: basic media 
supplemented with 1 mg.mL-1 BSA, 10 nM dexamethasone, 50 µg.mL-1 ascorbic acid 
and 10 mM β-glycerophosphate for 14 days. After differentiation, the cells were 
washed with sterile PBS and fixed in 70 % (v/v) methanol at -20 °C for 30 minutes. The 
fixed cells were washed twice with distilled water and osteogenic differentiation 
detected by incubation of the cells for 10 minutes at room temperature with 40 mM 
alizarin red (pH’d to 4.1 with ammonium hydroxide). Stain was removed and cells 
washed five times with distilled water before imaging. 
MSC Chondrogenesis  
BM-MSCs were placed in micromass culture: 5x105 cells in 50 µL of basic media with 10 
% (v/v) FCS were pipetted as a droplet in a 12 well plate and left to attach for 24 hours. 
The culture medium was gently removed and the cell micromasses were cultured for 
14 days in chondrogenic media: basic media supplemented with 1 mg.mL-1 BSA, 100 
nM dexamethasone, insulin transferrin and selenium (ITS), 50 µg.mL-1 ascorbic acid and 
10 ng.mL-1 transforming growth factor (TGFβ). After differentiation, the micromasses 
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were washed with sterile PBS and fixed in 70 % (v/v) methanol at -20 °C for 30 minutes. 
Fixed cells were then washed twice with distilled water and chondrogenic 
differentiation detected by incubation of the cells with 3 % (v/v) acetic acid for 1 
minute followed by 1 % (v/v) alcian blue (1 g alcian blue in 100 mL acetic acid, pH 2.5, 
filtered) for 18 hours at room temperature. The micromasses were then 
counterstained with 0.05 % (w/v) neutral red (0.5 g neutral red in 100 mL distilled 
water). The stain was removed and cells washed five times with distilled water before 
imaging. 
4.2.3 3D Cell Culture 
4.2.3.1 Pellet Culture  
Cells were expanded until passage 2 and trypsinised as previously described in Section 
4.2.2.3. A cell count was performed using a haemocytometer and 5x105 cells were 
suspended in 0.5 mL of basic media in a 20 mL tube. The cells were then centrifuged at 
1000 rpm for 5 minutes to form a cell pellet. The pellet was allowed to form for 24 
hours in a humidified atmosphere of 5% CO2/95% air at 37 °C. The basic media was 
then carefully removed as not to disrupt the pellet and replaced with 2 mL of 
differentiation media. The pellets were then cultured for 21 days in differentiation 
media.  
4.2.3.2 Scaffold Preparation 
Biofelt® PGA scaffolds (Cellon, Luxemburg) and electrospun PLLA were both cut to a 
diameter of 6 mm using a cork borer. Scaffolds were then sterilised for 15 minutes in 
isopropanol. Once sterile, the scaffolds were washed three times in sterile PBS and 
conditioned in Basic media with 10 % (v/v) FCS for a further 15 minutes.  
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4.2.3.3 Scaffold Seeding and Culture 
Cells were expanded until passage 2 cells and trypsinised as previously described in 
section 4.2.2.3. A cell count was performed using a haemocytometer and 2x106 cells 
were suspended in expansion medium and then seeded on the scaffolds as follows. 
Scaffolds were placed in sterile, non-tissue culture treated sterile 9 cm dishes (2 
scaffolds per dish), the appropriate number of cells (4x 106 cells/2 scaffolds)  was 
added  and cells allowed to attach for 72 hours  at 37 °C in a humidified atmosphere of 
5 % CO2/95 % air on an orbital shaker set at 35 rpm.  
After 72 hours a cell count of the unattached cells present in the culture media was 
performed to assess the level of cell attachment which had occurred. The cell-seeded 
scaffolds (constructs) were placed into a 6 well plate (1 construct  per well) and 
cultured in differentiation media for 42 days at 37 °C in a humidified atmosphere of 5 
% CO2/95 % air on an orbital shaker set at 30 rpm. The Differentiation media was 
changed every 3 days. 
4.2.3.4 Bioreactor Culture 
The Quasi-vivo® bioreactor chamber (Kirkstall Ltd, UK), media reservoir and tubing was 
sterilised at 121 °C for 15 minutes and washed with sterile PBS. After seeding in sterile, 
non-tissue culture treated 9 cm dishes; the resulting constructs were placed within the 
culture chambers (Figure 4-2) and cultured in differentiation media for 42 days at 37 °C 









Figure 4-2: Bioreactor set up showing the peristaltic pump, media reservoir and culture 
chamber. (A) photograph of the bioreactor set up in a laminar flow hood; (B) a 
schematic diagram of the flow through the bioreactor system. 
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4.2.3.5 Differentiation Media 
 Chondrocyte Hypertrophic Differentiation Media 
Chondrocytes were differentiated using basic media supplemented with 10 % (v/v) FCS, 
1 µg.mL1 insulin and 50 µg.mL-1 ascorbic acid as described by Kwarciak et al (Kwarciak, 
2009). 
MSC Hypertrophic Differentiation Media 
BM-MSCs were seeded in basic media supplemented with 5 % (v/v) FCS, 1 mg/ml BSA 
and 100 nM dexamethasone. Chondrogenic media was then used for 14 days: basic 
media supplemented with 1 mg.mL-1 BSA, 10 µl.mL-1, 100 μl.mL-1 10X ITS (1.0 mg.mL-1 
recombinant human insulin, 0.55 mg.mL-1 human transferrin (substantially iron-free), 
0.5 μg.mL-1 sodium selenite, 470 μg.mL-1 linoleic acid, 470 μg.mL-1 oleic acid and 50 
mg.mL-1 bovine FCS albumin), 100 nM dexamethasone, 50 µg.mL-1 ascorbic acid and 10 
ng.mL-1 TGFβ1. The culture medium was then changed to a hypertrophic differentiation 
media: basic media supplemented with 1 mg.mL-1 BSA, 100 μl.ml-1 10X ITS, 100 nM 
dexamethasone, 50 µg.mL-1 ascorbic acid and 1 nM thyroxine for the remaining 14 days 
of the culture period. 
Serum-free Chondrocyte Hypertrophic Differentiation Media 
Serum-free differentiation was carried out without the use of FCS. Three media were 
tested:  
Media 1: basic media supplemented with 1 mg.mL-1 BSA, 1 µg.mL1 insulin and 50 
µg.mL-1 ascorbic acid. 
Media 2: basic media supplemented with 1 mg.mL-1 BSA, 100 μl.mL-1 10X ITS and 50 
µg.mL-1 ascorbic acid. 
PhD Thesis                                                                                                               Bardsley 2014 
47 
 
Media 3: basic media supplemented with 1 mg.mL-1 BSA, 100 μL.mL-1 10X ITS and 50 
µg.mL-1 ascorbic acid and 1 nM thyroxine. 
4.2.4 Histological and Biochemical Analysis 
4.2.4.1 Cryopreservation and Weighing of Grafts 
After 42 days of culture the constructs were removed and washed in PBS, gently 
blotted with tissue to remove excess liquid and each construct cut into two equal-sized 
pieces with a scalpel. For each construct, half the construct was weighed and placed in 
a 2 mL conical centrifugation tube, which was stored at -20 °C until required for a GAG 
assay. The other half of the scaffold was embedded in optimum cutting temperature 
tissue mounting medium (OCT) (cut side facing upwards) on a cork disc, in a beaker of  
isopentane (Fisher Scientific, Loughborough, UK) held in liquid nitrogen, wrapped in 
Parafilm  and stored at -20 °C until required for  histological and immunohistochemical 
analysis.  
4.2.4.2 Histology and Immunohistochemistry 
OCT embedded constructs were sectioned at a thickness of 8 μm using a cryostat and 
mounted on to 3-aminipropyltriethoxysilane (APES) coated slides and allowed to dry 
overnight. 
Haematoxylin and Eosin Staining 
Sections on APES slides were fixed in 4 % (w/v) paraformaldehyde (PFA) (pH 7.2-7.4) 
for 30 minutes at 4 °C. The sections were then washed in PBS and dried overnight.  
Haematoxylin and Eosin staining was carried out using an automatic staining machine 
(Shandon, Runcorn, UK). The slides were first placed in haematoxylin washed in 1 % 
acid alcohol, Scotts tap water and tap water before being stained with eosin. The 
stained sections were washed again in water, dehydrated through alcohols, cleared in 
xylene and mounted in DPX (Fisher Scientific, Loughborough, UK). 




Sections on APES slides were fixed in 4 % (w/v) PFA (pH 7.2-7.4) for 30 minutes at 4 °C. 
The sections were then washed in PBS and dried overnight.  Tissue sections were 
rinsed in 3 % (v/v) acetic acid and stained with 1 % (w/v) alcian blue in acetic acid (pH 
2.5) for 18 hours before being counterstained with 0.5 % (w/v) aqueous neutral red in 
distilled water for 1 minute. The stained sections washed in distilled water, cleared in 
xylene and mounted in DPX. 
Toluidine Blue 
Sections on APES slides were fixed in 4 % (w/v) PFA (pH 7.2-7.4) for 30 minutes at 4 °C 
followed by washing in PBS and then dried overnight.  The fixed sections were stained 
with 1 % (w/v) toluidine blue in 0.5 % (w/v) sodium borate for 10 seconds, washed in 
distilled water, cleared in xylene, air dried overnight and mounted in DPX. 
Alkaline Phosphatase 
Sections on APES slides were fixed in 70 % (v/v) ice cold methanol (Fisher Scientific, 
Loughborough, UK) at -20 °C for 30 minutes. The tissue sections were then washed in 
PBS and dried overnight.  A SIGMAFASTTM BCIP®/NBT (5-bromo-4-chloro-3-indoyl 
phosphate/ Nitro blue tetrazolium) tablet was dissolved in 10 mL of distilled water. The 
tissue sections were then incubated with the SIGMAFASTTM BCIP®/NBT solution for 15 
minutes at room temperature (alkaline phosphatase was detected as a blue/black 
colour change) and washed in distilled water and mounted in DPX.  
Alizarin Red Staining 
Sections were fixed in 70 % (v/v) ice cold methanol at -20 °C for 30 minutes. The tissue 
sections were then washed in PBS and dried overnight. Sections were stained with 
alizarin red solution (342 mg of alizarin red in 25 mL of distilled water and pH adjusted 
to 4.1 with 10 % (v/v) ammonium hydroxide) for 10 minutes, washed in distilled water 
and mounted using aqueous mount. 
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Immunolocalisation of Collagens 
Sections on APES slides were fixed in 4 % (w/v) paraformaldehyde (pH 7.2-7.4) (PFA) 
for 30 minutes at 4 °C. The tissue sections were then washed in PBS and dried 
overnight.  
Fixed sections were pre-treated with 10 mg.mL-1 bovine testicular hyaluronidase in PBS 
and 2 mg.mL-1 pronase from Streptomyces Griseus in PBS for 30 minutes at 37 °C in a 
humidified atmosphere and washed for 10 minutes in PBS. Endogenous peroxide 
activity was quenched with 3 % (v/v) hydrogen peroxide (30 wt % solution) in 50 % 
(v/v) methanol for 5 minutes. The sections were then washed for 10 minutes in PBS 
before being incubated with 3 % (w/v) BSA and 10 % (v/v) horse serum blocking 
solution for 1 hour to avoid non-specific staining. The sections were incubated for 15 
hours at 4 °C with the appropriate primary antibodies: goat anti-collagen type II (0.4 
mg.mL-1, dilution 1:20) (Cambridge Bioscience, Cambridge, UK); Mouse anti-collagen 
type X, (0.4 mg.mL-1, dilution 1:100) (Quartett, Berlin, Germany); rabbit anti-collagen 
type X, (0.4 mg.mL-1, dilution 1:50) (AbCam, UK) and blocking solution controls. The 
tissue sections were washed three times for 10 minutes with PBS and incubated with 
the appropriate biotintylated secondary antibodies: biotintylated rabbit anti-goat IgG 
(dilution 1:100) (Vector Laboratories, UK); biotintylated rabbit anti-goat IgG (dilution 
1:100) (Vector Laboratories, UK); biotintylated horse anti-mouse (rat adsorbed) IgG 
(dilution 1:100) (Vector Laboratories, UK) for 1 hour. The tissue sections were washed 
three times for 10 minutes in PBS and incubated with ABC reagent from the 
Vectastain® Kit (Vector Laboratories, UK) for 30 minutes at room temperature before 
undergoing three further washes in PBS. Diaminobenzidine tetra hydrochloride (DAB) 
substrate (Vector Laboratories, Peterborough, UK) was prepared following the 
manufacturer’s instructions before being applied to tissue sections for 2-10 minutes 
until a suitable brown colour developed. The sections were then counterstained with 
haematoxylin and mounted with DPX. 
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4.2.4.3 Glycosaminoglycan Assay 
Proteoglycan content of the tissue engineered constructs was assessed by measuring 
the amount of glycosaminoglycans (GAG) in the ECM. The constructs were weighed 
after and freeze dried overnight before being re-weighed in order to assess the water 
concentration within the construct. Freeze dried constructs were then digested 
overnight in a papain digestion buffer (0.05 % (w/v) papain (from papaya latex) and 6 
mM n-acetyl cysteine in 200 mM phosphate buffer containing 1 mM EDTA, pH 6.8) at 
60 °C.  
The GAG concentration was then analysed using diethylmethylene blue (DMB) 
following the protocol described by (Farndale et al., 1986). DMB (10 mM in ethanol 
(Fisher Scientific, UK) was further dissolved into 500 mL distilled water containing 40 
mM  glycine and 40 mM sodium chloride, with pH adjusted to 3 using hydrochloric 
acid). 50 µL of sample was then mixed with 250 µL of DMB and the optical density was 
measured at 525 nm (530-10 absorbance filter) using the spectrophotometer. This 
reading was then compared to a chondroitin sulphate standard curve to give a GAG 
concentration present in the sample. Total percentage matrix was then calculated 
using the following formula: 
                           
           
                    
       
4.2.5 Gene Expression     
The gene expression of the chondrocytes was assessed at various time points, as 
shown in the schematic (Figure 4-3) The gene expression was then either normalised to 
chondrocytes at passage 2 on tissue culture plastic or after 3 days on the scaffold 
materials in expansion media. 










Figure 4-3: Schematic diagram showing the experimental plan and the time points at 
which the gene expression of the chondrocytes will be assessed 
 
4.2.5.1 RNA Extraction 
After culture the tissue engineered constructs were washed in PBS and flash frozen in 
liquid nitrogen for 30 seconds. A tissue pulveriser was then used for 1 minute in order 
to homogenise the sample in PBS. The homogenised sample was then centrifuged at 
11,0000 rpm for 2 minutes in order to gain a tissue pellet. RNA was extracted 
immediately from this tissue pellet using the Bioline Isolate II RNA Mini Kit (Bioline 
Reagents Ltd, UK) and the RNA concentration determined using a NanoDrop 2000. 
Isolated RNA was diluted to a concentration of 10 ng.µL-1 using Rnase free water and 
stored at -80 °C until it was required for cDNA synthesis.  
4.2.5.2 Reverse Transcription Polymerase Chain Reaction  
cDNA was synthesised using a high capacity RNA to cDNA master mix (Life 
Technologies, UK) and 100 ng of RNA in total per reaction.  
PhD Thesis                                                                                                               Bardsley 2014 
52 
 
Table 4-1 gives the composition of a cDNA synthesis reaction, these reactions were run 
in a thermal cycler using a cycle of 10 minutes at 25 °C, 2 hours at 37 °C, 5 minutes at 
85 °C and then 10 minutes at 4 °C. cDNA was then stored at -20 °C until real time PCR 
was performed. 
Table 4-1: Composition of reagents per cDNA synthesis reaction 
 
Reagent 
Volume per reaction 
(µL) 
Master Mix 
Reverse transcription buffer 2 




Multiscribe Reverse Transcriptase 1 
Nuclease free water 4.2 
Sample RNA (10ng/µL) 10 
 
4.2.5.3 Real Time Polymerase Chain Reaction  
Real time PCR was performed using a 7900Fast Real Time PCR machine in a 96 well 
plate with an experimental volume of 10 µL. Table 4-2 shows the reagents (Life 
Technologies, UK) required per real time PCR reaction. Three technical repeats were 
performed per reaction.  
 
 




Table 4-2: Composition of reagents per real time PCR reaction 
Reagent 
Volume per reaction 
(µL) 
Taqman mastermix 5 
Nuclease free water 3.5 
Target primer/probe 0.5 
Endogenous control primer/probe (GAPDH) 0.5 
cDNA sample (5 ng/µL) 0.5 
 
Taqman probes and primers were used for the detection of the expression of collagen 
type II, collagen type X, alkaline phosphatase, Ihh, sox9 and runx2 (Life Technologies, 
UK). Non template and reverse transcriptase negative controls were used to check for 
cDNA contamination. Table 4-3 shows the assay identification numbers for the primers 
and probes used for q-PCR. 
Results were analysed using the ΔΔct method in relation to the housekeeping gene, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. The ΔΔct value was 
then normalised to either a). gene expression of undifferentiated chondrocytes on 2D 
culture plastic, for comparison between the scaffolds, or b). undifferentiated 3D 
culture chondrocytes, to assess the differentiation on the scaffolds. 
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Table 4-3: Taqman primer and probe identification numbers of assays used during q-
PCR. 
Gene Taqman primer and probe assay number 
Collagen type II, alpha 1 Rn01637087_m1 
Collagen type X, alpha 1 Rn01408030_m1 





4.2.6 Construct Decellularisation 
This protocol was adapted from a protocol for the decellularisation of articular 
cartilage published by Kheir et al (Kheir et al., 2011). 
The tissue constructs were removed from culture and washed with PBS before 
undergoing three, freeze-thaw cycles. The constructs were frozen at -20 °C for 2 hours 
before being thawed at room temperature for 2 hours. The freeze thaw cycles were 
then repeated with the grafts submerged in hypotonic buffer (10 mM Tris- HCl, pH 8.0, 
filter sterilised, with the addition of protease inhibitors). The constructs were then 
placed in an ionic buffer (0.1 % (w/v) sodium dodecyl sulphate (SDS), 0.1 % (w/v) EDTA 
in distilled water, filter sterilised, with the addition of protease inhibitors) and left for 1 
hour gently shaking at room temperature on an orbital shaker (at 100 rpm), before 
being transferred to hypertonic buffer for 1 hour on an orbital shaker (at 100 rpm) at 
room temperature.  The tissue constructs were cycled through ionic and hypotonic 
buffers three times in order to lyse the chondrocytes in the construct. The constructs 
were then decontaminated using a 0.1 % (v/v) peracetic acid solution for 1 hour on an 
PhD Thesis                                                                                                               Bardsley 2014 
55 
 
orbital shaker at 100 rpm.  The constructs were then washed 3 times with sterile PBS. 
The degree of decellularisation was assessed by DNA quantification (Section 4.2.6.1) 
and 4’,6-diamidino-2-phenylindole (DAPI) staining (Section 4.2.6.2)  and its effect on 
the extracellular matrix content was assessed using the glycosaminoglycan assay 
(Section 4.2.4.3). 
4.2.6.1 DNA Quantification 
DNA was isolated from the tissue constructs both pre and post decellularisation to 
assess the efficacy of the decellularisation process. Constructs were weighed before 
extraction with Trizol® reagent (Life Technologies, UK). Trizol® (0.5 mL) was added to 
each construct and the construct, homogenised and incubated for 5 minutes at room 
temperature. Chloroform was added (0.1 mL), shaken vigorously, incubated for 2 
minutes and centrifuged at 12,000 g for 15 minutes at -4 °C. The aqueous phase was 
removed and ethanol (0.15 mL/sample) was added and the samples incubated for 2 
minutes and then centrifuged at 2,000 g for 5 minutes at 4 °C. The supernatant fraction 
was removed and the pellets were incubated with 0.1 M sodium citrate in 10 % (v/v) 
ethanol solution (0.5mL) for 30 minutes and before being re-centrifuged at 2,000 g for 
5 minutes at 4 °C. The supernatants were removed and 75 % (v/v) ethanol added to the 
pellets (1 mL/pellet) incubated for 15 minutes and centrifuged at 2,000 g for 5 minutes. 
The pellets were air dried before being re-suspended in 8 mM sodium hydroxide (0.3 
mL/pellet). The DNA was then quantified using the NanoDrop 2000.  
4.2.6.2 4’,6-diamidino-2-phenylindole Staining 
8 µm cryosections were cut from OCT mounted constructs and transferred to  APES 
coated slides and fixed in 4 % (w/v) PFA for 10 minutes. The tissue sections were 
washed with PBS three times for 5 minutes. The chondrocytes were permeabilised in 
0.1 % (v/v) Triton-X-100 for 10 minutes and PBS washes were repeated. The 
chondrocytes were stained with DAPI for 15 minutes in the dark. The tissue sections 
were then washed in PBS and imaged with a fluorescence microscope. When bound to 
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double-stranded DNA DAPI has an absorption maximum at a wavelength of 358 nm 
(ultraviolet) and its emission maximum is at 461 nm (blue). Therefore, for fluorescence 
microscopy DAPI is excited with ultraviolet light and is detected through a blue/cyan 
filter. 
4.2.7 In Vivo Experiments 
In vivo experiments were carried out using tissue engineered constructs formed from 
rat nasal chondrocytes grown on PGA. The constructs were placed in 4 mm full 
thickness healing defect in the cranium of 8 week old Wistar rats (Figure 4-4). All in vivo 
work was carried out by Christine Freeman under the appropriate animal license 
(license number: 40/3311). 
Rats were placed under anaesthetic using IsoFlo (Isofluorane) (Abbott Laboratories, 
UK) and given antibiotics, Synulox (Pfizer, UK), and a painkiller, Metacam (Boehringer-
Ingleheim, Germany). Once under anaesthetic, the rats were weighed. A midline 
incision was made in the skin covering the skull and both the skin and periosteum were 
retracted to reveal the cranium. Two 4 mm full thickness defects were drilled into the 
skull using a 3.5 mm diamond burr with saline irrigation. Grafts were cut to 4 mm 
diameter using a sterile biopsy punch and placed into one of the defects with the other 
being left empty. The periosteum was closed over the defects and secured with 2 vicryl 
stitches, before the wound was closed using 4-5 stitches. Anaesthetic was turned off 
and the animal given oxygen for 3 minutes.  




Figure 4-4: Schematic of operation showing the positioning of the two 4 mm defects in 
the skull and the filling of one defect with a construct. 
Constructs were allowed to heal the defect for 4, 8 and 12 weeks, before the animals 
were culled. Rats were anesthetised using IsoFlo and their vertebrae separated, the 
heads were then removed from the animal and placed in 10 % (w/v) neutral buffered 
formalin and stored at room temperature. The rat heads were then examined by 
microCT and histology to assess the degree of new bone formation in the defect area. 
4.2.7.1 ‘Living’ Grafts 
Constructs were removed from the culture after 35 days and washed in PBS twice 
before implantation in to the bone defects. 
4.2.7.2 Decellularised Grafts 
Constructs were removed from culture after 35 days and decellularised using the 
protocol described in section 4.2.6 before being implanted into the bone defects. 
4.2.7.3 Recellularised Grafts 
Constructs were removed from culture after 35 days and decellularised using the 
protocol described in section 4.2.6. The decellularised constructs were then 
recellularised with BM-MSCs using the following methodology. BM-MSCs were 
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described previously (Section 4.2.2.2) and cultured until passage 2 (Section 4.2.2.3). 48 
hours before implantation, the cultures of BM-MSCs were trypsinised using the 
protocol described in section 4.2.2.3 and a cell count was performed using a 
haemocytometer. Decellularised constructs (4 mm diameter) were placed in culture 
dishes and 1 x105 cells in basic media with 5 % (v/v) FCS, 1 mg.mL-1 BSA and 10 nM 
dexamethasone added per construct. The culture dishes were incubated on an orbital 
shaker set to 35 rpm at 37 °C humidified atmosphere of 5 % CO2/95 % air for 48 hours 
to enable cell seeding to occur. The BM-MSC-seeded constructs were then implanted 
into the bone defects. 
4.2.7.4 Microcomputed Tomography Analysis 
Rat heads were fixed in 10 % (w/v) neutral buffered formalin and analysed using a 
desktop high resolution microcomputed tomography (microCT) system (Skyscan 1172, 
Skyscan, Belgium). The heads were placed horizontally into a polyethylene tube in the 
system and rotated, while the x-rays originated from a point source. Scans were 
performed at 100 kVp, with a 1 mm aluminium filter and a pixel size of 12.1 μm. 
Images were taken throughout 360 ° with 2 images being averaged at each point.  
4.2.7.5 Decalcification of Rat Skulls 
After microCT analysis the rat heads were skinned and all the soft tissue was removed. 
The skulls were then placed in a neutral aqueous solution of 0.5 M EDTA and 0.4 M 
sodium hydroxide in distilled water pH 7.0 for 14 days changing the EDTA solution 
every 7 days as the EDTA becomes saturated with calcium. Skulls were then X-rayed to 
check that the calcium had been removed from the bone. 
4.2.7.6 Paraffin Wax Embedding and Sectioning 
The skulls were washed in running water for 20 minutes before being dehydrated 
through alcohols and embedded in molten paraffin wax. The wax blocks were cooled 
for 30 minutes on ice and 5 μm sections were then cut using a microtome. Sections 
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were then stained using heamatoxylin and eosin (Section 4.2.4.2) and alcian blue 
(Section 4.2.4.2). 
4.2.8 Statistical Analysis  
All statistical analysis was performed using Graphpad software. Initially a  D'Agostino-
Pearson “omnibus K2" test was performed to check the normality of the data. 
Significance between two groups of data was then analysed using the student t-test. 
For comparison between three or more groups of data a one way ANOVA, followed by 
Tukey’s test was used to assess the significant changes in the data. Significance was 
observed with data exhibiting a p value less than 0.05. 




5.1 Scaffold Fabrication 
Scaffolds were fabricated by electrospinning PLLA to create randomly aligned fibre 
mats (Figure 5-2). These scaffolds were also modified using an alternate soaking 
protocol (Section 4.2.1.2) to create a composite PLLA/calcium phosphate scaffold 
material. 
After treatment with the alternative soaking protocol the dry weight of the electrospun 
PLLA scaffold material significantly increased (Figure 5-1), suggesting that mineral 
material had been deposited in between or on the scaffold fibres. Imaging the 
composite scaffolds with SEM showed that a precipitate was present both in between, 
and on the scaffold fibres after treatment with the alternate soaking protocol (Figure 
5-2). When comparing the SEM images of the electrospun PLLA and the PGA (Figure 
5-2 and Figure 5-3 respectively), it can be seen that the fibre diameter and the pore 
size of the commercial PGA is larger. The precipitate was analysed using XRD and was 
found to consist of 2 phases of calcium phosphate, hydroxyapatite and brushite (Figure 
5-4).  
Contact angle determination was also performed on both the experimental PLLA and 
commercial PGA scaffold materials. The addition of calcium phosphate led to a 
decrease in the contact angle of distilled water with the scaffold material (Table 5-1), 
when compared to the PLLA alone and the commercial PGA.  
 


















Figure 5-1: Weight of the PLLA scaffolds both pre-treatment and post-treatment by the 
alternative soaking technique to form a PLLA/calcium phosphate composite scaffold. 
(*** = p<0.001. n= 6). 
 
Figure 5-2: Randomly oriented electrospun PLLA polymer fibres, (A, B) before 
alternative soaking; (C, D) after alternative soaking. The scale bars in images A, B and D  










Figure 5-3: Scanning electron microscopy image of the non-woven needle punched 
PGA scaffold purchased from Cellon. (scale bar = 50 μm) 




Figure 5-4: Representative XRD analysis of the precipitate on and within the PLLA fibres. This shows the presence of two phases of 
calcium phosphate, hydroxyapatite (      grey) and brushite (      red) in the precipitate (n=3 ). 
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Table 5-1: Measurement of the contact angle of water on the surface of the scaffold 
material. Analysis was performed on 3 individual specimens per scaffold group, the 
results are expressed as the means +/- standard deviations 
Scaffold Material Contact Angle 
Electrospun PLLA 70 ± 3 ° 
PLLA/Calcium phosphate 15 ± 1 ° 
PGA 60 ± 4 ° 
 
5.2 The Effect of Serum on Chondrocyte Hypertrophy 
Initial experiments of rat nasal chondrocytes cultures on PGA did not result in complete 
hypertrophic differentiation of the grafts after 42 days of culture. The constructs were 
observed to be heterogeneous in cell composition, with small pockets of 
morphologically large hypertrophic cells expressing collagen type X and alkaline 
phosphatase surrounded by large areas of smaller undifferentiated cells (Figure 5-4). 
FCS batch testing was therefore undertaken to find a FCS which promoted the growth 
and proliferation of the chondrocytes without inhibiting the hypertrophic 
differentiation pathway. Table 5-2 shows the information on the 5 batches of FCS that 
were tested. For batch testing, pellet cultures of nasal chondrocytes were used to 
investigate the chondrogenic capacity of the sera (Section 4.2.3.1) and nasal 
chondrocyte/PGA constructs were used to investigate the effect of the sera on the 
ability of the chondrocytes to undergo hypertrophy (Section 4.2.3.3). The chondrogenic 
capacity of the sera was investigated by measurement of the amount of GAG in the 
pellet cultures. Hypertrophy of the chondrocyte constructs was monitored by histology 
to examine cell morphology and immunolocalisation of collagen type X. 





Figure 5-5: Immunohistochemical analysis of rat nasal chondrocyte constructs after 42 
days culture. (A) haematoxylin and eosin Stain; (B) toluidine blue; (C) alcian blue; (D) 
alkaline phosphatase; (E) collagen type II; (F) collagen type X. (Insert micrographs show 
non-specific staining). Arrows indicate areas of hypertrophy as shown by chondrocytes 
exhibiting a large morphology co located with high GAG concentrations and collagen 
type X expression. 
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Table 5-2: Manufacturer and batch number of the five FCS batches tested for 
chondrocyte growth and hypertrophic differentiation 
FCS Number Manufacturer Batch Number 
1 Biosera S1900.050 
2 Biosera S10830.050 
3 Sigma F9665 
4 Sigma F7524 
5 Biosera - 
 
As shown in Figure 5-6, the concentration of GAG within the constructs, which is 
indicative of the proteoglycan content of the extracellular matrix varied greatly 
depending on the FCS used during the pellet differentiation experiments. FCS 3 and 4 
were shown to produce chondrocyte pellets with significantly lower GAG 
concentrations than FCS 1. However the changes in GAG were not significantly 
different when compared to FCS 5, which been used in previous experiments for the 
differentiation of rat nasal chondrocytes.  
Figure 5-7 illustrates that the hypertrophic differentiation of chondrocyte cultures on 
PGA after 3 weeks of differentiation is highly variable depending on the batch of FCS 
used. Whilst FCS 1 had the highest % GAG in the pellet culture (Figure 5-6) it is own to 
inhibit the differentiation of chondrocytes down the hypertrophic pathway. Full 
hypertrophy of the construct was not expected after a 3 week culture period; however, 
hypertrophic chondrocytes should have been present after this period of culture. 
Constructs cultured using FCS 2, 4 and 5 have evidence of hypertrophic chondrocyte 
differentiation, which was demonstrated by not only the morphological increase in 
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chondrocyte cellular size (Figure 5-7) but also by the expression of hypertrophic marker 
collagen type X (Figure 5-7). FCS batch 4 was chosen for all further experiments as 
although the percentage GAG within the constructs is shown to be the lowest it did 
allow for the most extensive hypertrophy within the constructs, with comparable levels 
to that seen using FCS batch 5. FCS batch 4 was therefore used throughout the 
following experiments to ensure and that the degree of hypertrophy obtained between 


























































Figure 5-6: DMB assay showing the GAG concentration present in the PGA pellets 21 
days after culture in the 5 different sera (* p <0.05, **p <0.01, n=5).  
** 
* 




Figure 5-7: Representative analysis of constructs cultured in FCS 1-5, showing the 
degree of hypertrophic differentiation seen after three weeks of culture. Haematoxylin 
and eosin staining showed the increase in cellular volume co-located with expression of 
the hypertrophic marker collagen type X (magnification x10, scale bars = 200 µm, insert 
micrographs show negative controls, n=5) 
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5.3 Hypertrophic Differentiation of Rat Nasal Chondrocytes 
Both the experimental (electrospun PLLA and electrospun PLLA/calcium phosphate) 
and commercial (PGA) scaffold materials were assessed for their ability to support 
chondrocyte attachment, proliferation and hypertrophic differentiation after 42 days 
of culture in differentiation media.  
Initial chondrocyte attachment studies showed that the PGA and PLLA/calcium 
phosphate scaffold allowed for comparable levels of attachment after 72 hours (84.75 
% and 87 % respectively) (Figure 5-8). The PLLA, however, resulted in a significantly 































Figure 5-8: Chondrocyte attachment to PGA, PLLA and PLLA/calcium phosphate scaffold 
materials after 72 hours on a shaker plate. (** p< 0.001, n=6) 
After a 42 day culture period on the scaffold materials, the chondrocytes exhibited 
hypertrophic differentiation on the PGA and PLLA/calcium phosphate scaffolds. 
Hypertrophy was shown by the chondrocytes exhibiting an increase in cellular volume 
with co-localisation of hypertrophic markers collagen type X and alkaline phosphatase 
(Figure 5-10)) in the ECM. The constructs formed form either PGA or PLLA/calcium 
** 
** 
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phosphate composite scaffolds were also positive for collagen type II expression and 
stained strongly with toluidine blue and alcian blue showing GAG present in the ECM. 
The electrospun PLLA scaffold material, however, was unable to produce a 
homogenous construct, with small clusters of hypertrophic cells being formed on the 
scaffold surface. These chondrocyte clusters while expressing collagen type X, did not 
express alkaline phosphatase. The PLLA constructs also stained weakly with alcian blue 
or toluidine blue suggesting that there was low GAG accumulation within the ECM. Due 
to the poor performance of the PLLA scaffold material no further investigations using 
this scaffold material were performed. 
The presence of GAG in the constructs was confirmed by the quantification of GAG 
within the construct ECM after 42 days of culture. The percentage of GAG accumulated 
within the ECM by PGA and PLLA/calcium phosphate-based constructs was 
comparable, with an average of 12.91 % and 14.10 % respectively of the dry weight of 
the ECM being constituted of GAG. When culturing on the PLLA scaffold material only 
0.28 % of the ECM was found to be composed of GAG (Figure 5-11). 
GAG production using the PLLA/calcium phosphate scaffold was also compared to that 
achieved using the PGA scaffold material throughout the culture period (Figure 5-12). 
The PLLA/calcium phosphate scaffold material allowed a higher GAG accumulation 
earlier on in the culture, with significantly higher percentage GAG being seen at day 14 
and 28 compared to the PGA scaffold (Figure 5-12). However by day 42 the percentage 
of GAG while still higher is not significantly increased when using the new PLLA/calcium 
phosphate composite scaffold material (Figure 5-12).  
No mineralisation of construct ECM was observed using the PGA scaffold material, 
while some alizarin red staining was observed in the PLLA/calcium phosphate 
constructs where staining was within or along the surface of the scaffold material with 
little staining seen within the tissue itself (Figure 5-13). Due to the intense loss in 
alizarin red staining in the PLLA/calcium phosphate this alizarin red staining may well 
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be due to the release of calcium ions from the scaffold which are entrapped within the 
tissue




Figure 5-9: Histological and immunohistochemical analysis of constructs formed by culturing chondrocytes on PGA, PLLA and 
PLLA/calcium phosphate scaffold materials for 42 days. The images show haematoxylin and eosin; toluidine blue and alcian blue 
staining. (n=10). Scale bars = 100 µm. 




Figure 5-10: Histological and immunohistochemical analysis of constructs formed by culturing chondrocytes on PGA, PLLA and 
PLLA/calcium phosphate scaffold materials for 42 days. The images show collagen type II; collagen type X and alkaline phosphatase 
staining. Insert micrographs show non-specific staining (n=10). Scale bars = 100 µm. 














































Figure 5-11: GAG content of chondrocyte constructs (expressed as a percentage of the 
dry weight of the ECM) after 42 days of culture on PGA, PLLA and PLLA/calcium 
phosphate scaffolds. (**p<0.01, n=6) 
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Figure 5-12: A comparison of the GAG content in the extracellular matrix of constructs 
produced by chondrocytes cultured on PGA and PLLA/calcium phosphate scaffold 









Figure 5-13: Mineralisation present within the constructs after 42 days of culture under 
semi-static conditions. Images show staining for calcium using alizarin red on the PGA 
scaffold material (A) and the PLLA/calcium phosphate composite scaffold material (B). 
(C) Shows alizarin red staining of the PLLA/calcium phosphate scaffold at day 0 of 
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5.4 Protein and Gene Expression during Chondrocyte Hypertrophic 
Differentiation on PGA and PLLA/Calcium Phosphate Scaffold Materials 
In order to further understand the process of hypertrophic differentiation of the nasal 
chondrocytes, the ECM gene and protein expression was investigated as well as key 
signalling molecules, Ihh, and the transcription factors, sox9 and runx2. The two 
scaffold materials, PGA and PLLA/calcium phosphate composite were investigated for 
their effect on the expression of these key genes and proteins. 
5.4.1 The Effect of 3D Culture on Gene Expression 
Transferring chondrocytes from a monolayer (2D) culture to a 3D culture on the 
scaffolds was shown to have a significant impact on the gene expression of the 
chondrocytes after 24 hours. When using the PGA scaffold material, collagen type II, 
Ihh and sox9 expression by the chondrocytes in the construct was increased. However, 
the genes associated with hypertrophic differentiation, collagen type X and alkaline 
phosphatase, were decreased (Figure 5-14). However, transferring the chondrocytes 
from 2D culture to culture on the PLLA/calcium phosphate composite scaffold, 
however, had a different effect to culture on PGA. While the expression of 
hypertrophic associated genes (collagen type X, alkaline phosphatase and runx2) was 
reduced and the expression of Ihh remained increased, the expression of sox9 and 
collagen type II was reduced (Figure 5-15).  
 

















































































Figure 5-14: The effect of 3D culture of chondrocytes on the PGA scaffold material after 
72 hours in expansion culture media on gene expression. The data is normalised to the 
gene expression observed at passge 2 on tissue culture plastic (2D culture) (* p<0.05, 














































































Figure 5-15: The effect of 3D culture of chondrocytes on PLLA/calcium phosphate 
scaffold material on cell gene expression after 72 hours in expansion media. The data is 
normalised to the gene expression observed at passage 2 on tissue culture plastic (2D 




* * * ** 
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5.4.2 Extracellular Matrix Gene and Protein Expression on PGA and 
PLLA/calcium phosphate composite scaffolds 
When comparing gene expression on the PGA scaffolds to that of the PLLA/calcium 
phosphate scaffolds it was necessary to normalise the values to those of the 3D 
undifferentiated construct values so that the effect of the scaffold material on 
chondrocyte gene expression can truly be assessed. 
5.4.2.1 Collagen type II 
Collagen type II gene expression on both the PGA and PLLA/calcium phosphate scaffold 
material constructs also showed a significant increase in collage type II expression 
between day 3 and day 7 and was found to peak at day 7 of the culture with 4.97 and 
6.44 fold increases in expression observed respectively (Figure 5-16 and Figure 5-17 
respectively). The PGA scaffold, however, caused a significant downregulation of 
collagen type II gene expression by day 14, with lower levels than the collagen type 
gene expression observed in the undifferentiated 3D PGA scaffold culture, (Figure 
5-16). Both scaffold materials downregulated collagen type II expression throughout 
the culture with the lowest levels of expression being observed on day 42 of the 
culture (Figure 5-16 and Figure 5-17). Collagen type II was also deposited in the ECM of 
the constructs and was present throughout the culture period in both the PGA and 
PLLA/calcium phosphate scaffold constructs (Figure 5-26 and Figure 5-28 respectively). 
Collagen type II expression of the PLLA/calcium phosphate constructs was 
downregulated throughout the culture period when compared to collagen type II gene 
expression on the PGA scaffold material (Figure 5-18). At day 28 and day 42 the 
collagen type II gene expression was observed to be significantly downregulated in the 
PLLA/calcium phosphate scaffold constructs (Figure 5-18).  
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Figure 5-16: Collagen type II mRNA expression during hypertrophic differentiation on 
PGA scaffold material relative to its expression level seen after 72 hours of culture in 
expansion media (day 0 of 3D chondrocyte differentiation).  (*** p<0.001. n = 8) 
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Figure 5-17: Collagen type II mRNA expression during hypertrophic differentiation on 
PLLA/calcium phosphate scaffold material relative to the mRNA expression levels seen 
after 72 hours of culture in expansion media (day 0 of 3D chondrocyte differentiation).  








































Figure 5-18: Collagen type II mRNA expression in the chondrocytes during hypertrophic 
differentiation culture on PLLA/calcium phosphate scaffold material compared to 
expression seen on the PGA scaffold material. The data is normalised to the gene 
expression observed at passage 2 on tissue culture plastic (2D culture). (** p<0.01 and 
*p< 0.05. n = 8) 
5.4.2.2 Collagen type X 
Collagen type X mRNA expression significantly increased throughout the hypertrophic 
differentiation of the chondrocytes on both the PGA and PLLA/calcium phosphate 
scaffold materials between day 3 and day 35 (Figure 5-19 and Figure 5-20 respectively). 
The gene expression peaked at day 35 with an 85.69 and 77.49 fold increase compared 
to day 0 of culture on the scaffold material. However, there was a trend for the 
collagen type X gene expression, to decrease day 42 on both scaffold materials (Figure 
5-19 and Figure 5-20), although this trend did not reach significance. Collagen type X 
deposition within the matrix of both PGA and PLLA/calcium phosphate grafts by was 
detectable by immunohistochemical localisation by day 28, although its gene 
expression was upregulated by day 14. However, collagen type X protein was not 
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Figure 5-19: Collagen type X mRNA expression during hypertrophic differentiation on 
PGA scaffold material relative to mRNA expression levels seen after 72 hours of culture 
in expansion media (day 0 of 3D chondrocyte differentiation).    (** p<0.01. n = 8) 








































Figure 5-20 Collagen type X mRNA expression during hypertrophic differentiation on 
PLLA/calcium phosphate scaffold material relative to mRNA expression levels seen after 
72 hours of culture in expansion media (day 0 of 3D chondrocyte differentiation).  (* 
p<0.05. n = 8) 
** 
* 
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When compared to the constructs formed on the PGA scaffold material, constructs on 
the PLLA/calcium phosphate scaffold showed an upregulation of collagen type X 
throughout the culture period, with significant increases seen on days 14 and day 42 
(Figure 5-21).  
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Figure 5-21: Collagen type X mRNA expression during hypertrophic differentiation of 
chondrocytes cultured on PLLA/calcium phosphate scaffolds compared to the 
expression observed on the PGA. The data is normalised to the gene expression 
observed at passage 2 on tissue culture plastic (2D culture). (*p< 0.05. n = 8) 
5.4.2.3 Alkaline Phosphatase 
Alkaline phosphate mRNA expression of PGA constructs (Figure 5-22) followed a similar 
pattern to that shown by collagen type X (refer Figure 5-19 and Figure 5-21) with a 
significant increase in expression between day 3 and day 35, followed by a non-
significant decrease in expression at day 42. The PLLA/calcium phosphate constructs, 
however, give a continued increase of alkaline phosphatase throughout the culture 
* 
* 
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period up to day 42 (Figure 5-23). Unlike collagen type X, alkaline phosphatase activity 
was seen at the periphery of all the constructs at day 14 and was observed to increase 
throughout the culture period until day 42 where it was expressed throughout both 
the constructs made using both PGA and PLLA/calcium phosphate (Figure 5-26 and 
Figure 5-28) 
Alkaline phosphatase expression was upregulated in the PLLA/calcium phosphate 
scaffold constructs when compared to the PGA constructs, with a significant increase in 
expression observed at day 14 in the PLLA/calcium phosphate constructs (Figure 5-24). 
 
 
















































Figure 5-22: Alkaline phosphatase mRNA expression during hypertrophic differentiation 
of PGA constructs relative to mRNA expression levels seen after 72 hours of culture in 
expansion media (day 0 of 3D chondrocyte differentiation).   (*p< 0.05. n = 8). 
* 
PhD Thesis                                                                                                               Bardsley 2014 
84 
 































3 7 1 4 2 1 2 8 3 5 4 2
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
 
Figure 5-23: Alkaline phosphatase mRNA expression during hypertrophic differentiation 
of  PLLA/calcium phosphate constructs relative to mRNA expression levels seen after 72 
hours of culture in expansion media (day 0 of 3D chondrocyte differentiation).   (*p< 
0.05. n = 8). 
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Figure 5-24: Alkaline phosphatase mRNA expression of chondrocytes during 
hypertrophic differentiation of PLLA/calcium phosphate constructs compared to the 
alkaline phosphatase expression seen in the PGA constructs. The data is normalised to 
the gene expression observed at passage 2 on tissue culture plastic (2D culture). (*p< 
0.05. n = 8)  
* 
    * 
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Analysis of the gene expression and protein localisation of alkaline phosphatase in 
constructs at day 14, 28 and 42 of culture, showed the progression of the hypertrophic 
differentiation. At day 14, staining with alcian blue and toluidine blue was pale 
illustrating the low amount of ECM present. At this early stage of differentiation, the 
ECM present in the constructs consisted of mainly collagen type II and no collagen type 
X expression was seen (Figure 5-26 and Figure 5-28). However, alkaline phosphatase 
was expressed on the periphery of the constructs. By day 28 collagen type X and 
alkaline phosphatase were present within the ECM and were associated with 
chondrocytes with large cell morphology (Figure 5-26 and Figure 5-28). By day 42 all 
the constructs reproducibly displayed  hypertrophic features with chondrocytes with a 
have a large cellular volume and the ECM containing dense staining for collagen type X 
and alkaline phosphatase (Figure 5-26 and Figure 5-28).  
 




Figure 5-25: Representative histological analysis of chondrocytes grown on PGA scaffolds after 14, 28 and 42 days of culture, 
showing the localisation of extracellular proteins and within the ECM of the construct. Inset micrographs show negative controls, 
scale bars=100 µm (n=3 separate experiments).  




Figure 5-26: Representative immunohistological analysis of chondrocytes grown on PGA scaffolds after 14, 28 and 42 days of culture, 
showing the localisation of extracellular proteins and within the ECM of the construct. Inset micrographs show negative controls, 
scale bars=100 µm (n=3 separate experiments).  





Figure 5-27: Representative histological analysis of chondrocytes grown on PLLA/calcium phosphate scaffolds after 14, 28 and 42 
days of culture, showing the localisation of extracellular proteins within the ECM of the constructs. Inset micrographs show negative 
controls, scale bars=100 µm (n=3 separate experiments).   




Figure 5-28: Representative immunohistological analysis of chondrocytes grown on PLLA/calcium phosphate scaffolds after 14, 28 
and 42 days of culture, showing the localisation of extracellular proteins within the ECM of the constructs. Inset micrographs show 
negative controls, scale bars=100 µm (n=3 separate experiments).   
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5.4.3 Transcription Factor and Signalling Molecule Gene Expression 
5.4.3.1 Sox9 
The expression levels of sox9 were different between constructs formed from the 
different scaffold materials. After an initial increase in sox9 expression as chondrocytes 
were moved from 2D to 3D culture on PGA scaffolds, (Figure 5-14) the expression of 
sox9 was significantly reduced at day 3 of culture. After this initial inhibition, the 
expression of sox9 was not significantly altered (Figure 5-29). A trend for an increase in 
sox9 expression peak was seen at day 35 which corresponded to the time period when 
peaks in collagen type X expression and alkaline phosphatase expression were 
observed (Figure 5-19 and Figure 5-22). In the PLLA/calcium phosphate constructs, the 
expression of sox9 was initially downregulated as the chondrocytes were transferred 
from a 2D to the 3D culture environment. The expression of sox9 was then significantly 
upregulated between day 3 and day 14 (with a 99.93 fold increase). However a second 
peak in expression was seen at day 35 was observed during chondrocyte culture on 
both the PGA and the PLLA/calcium phosphate scaffolds.  
When sox9 mRNA expression on both scaffold materials was compared to the 2D 
culture hyaline chondrocytes sox9 is significantly upregulated in the PLLA/calcium 
phosphate constructs on day 14 of the culture. No such increase in sox9 gene 
expression was observed at day 14 in the PGA constructs. However, expression levels 
of sox9 were comparable on day 28 and day 42 (Figure 5-31).  














































Figure 5-29: Sox9 mRNA expression during hypertrophic differentiation of chondrocytes 
on PGA scaffolds relative to mRNA expression levels seen after 72 hours of culture in 
expansion media (day 0 of 3D chondrocyte differentiation). (*p< 0.05. n = 8). 
* 
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Figure 5-30: Sox9 mRNA expression during hypertrophic differentiation of chondrocytes 
on PLLA/calcium phosphate scaffolds relative to mRNA expression levels seen after 72 
hours of culture in expansion media (day 0 of 3D chondrocyte differentiation).   (***p< 
0.001. n = 8). 
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Figure 5-31: Sox9 mRNA expression in chondrocytes during hypertrophic differentiation 
on PLLA/calcium phosphate scaffolds relative to sox9 expression seen in chondrocytes 
cultured on the PGA scaffold.  The data is normalised to the gene expression observed 




PhD Thesis                                                                                                               Bardsley 2014 
93 
 
5.4.3.2 Indian Hedgehog 
 The expression profile of Ihh of both the PGA and PLLA/calcium phosphate constructs 
were shown to follow a similar temporal pattern, with a peak in Ihh expression 
observed at day 21 (Figure 5-32 and Figure 5-33 respectively), which was then 
significantly decreased by day 28. The relative fold expression was significantly higher 
for the PLLA/calcium phosphate constructs, peaking with a 62.40 fold increase, 
compared to a 20.32 fold increase in the PGA constructs.  However, this can be partly 
attributed to the lower increase in expression as the chondrocytes were moved on to 
the PLLA/calcium phosphate scaffold (Section 5.4.1).  
When comparing the two scaffold materials on the differentiation from 2D culture Ihh 
expression is seen to be significantly upregulated at day 14 and day 42 on the 
PLLA/calcium phosphate scaffold material when compared to the PGA scaffold material 
(Figure 5-34).  







































Figure 5-32: Ihh mRNA expression in the chondrocytes during hypertrophic 
differentiation culture on PGA relative to mRNA expression levels seen after 72 hours of 
culture in expansion media (day 0 of 3D chondrocyte differentiation). (* p<0.05. n = 8). 
* 
* 
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Figure 5-33: Ihh mRNA expression during chondrocyte hypertrophic differentiation on 
PLLA/calcium phosphate scaffolds relative to mRNA expression levels seen after 72 
hours of culture in expansion media (day 0 of 3D chondrocyte differentiation).  (*p< 
0.05. n = 8). 
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Figure 5-34: Ihh mRNA expression in the chondrocytes during hypertrophic 
differentiation culture on PLLA/calcium phosphate scaffolds material compared to Ihh 
expression seen in the PGA constructs. The data is normalised to the gene expression 









Runx2 was initially downregulated when the chondrocytes were transferred from 2D 
monolayer culture to culture on either the PGA scaffolds or PLLA/calcium phosphate 
scaffolds (Figure 5-14 and Figure 5-15). However, the expression profile was found to 
differ once the chondrocytes were cultured on the two scaffold materials. PGA 
constructs showed a gradual increase in runx2 expression over time in culture with a 
significant peak of runx2 expression at day 28 (Figure 5-35). Whereas, in PLLA/calcium 
phosphate constructs, a significant increase in runx2 expression was seen on day 3 of 
culture, after which the expression levels did not significantly alter throughout the 
differentiation period (Figure 5-36). 
When runx2 mRNA expression on both scaffold materials was compared to the runx2 
expression level in 2D cultured hyaline chondrocytes, the expression of runx2 was seen 
to be comparable throughout the culture period (Figure 5-37).  








































Figure 5-35: Runx2 mRNA expression during chondrocyte hypertrophic differentiation 
on PGA scaffolds relative to mRNA expression levels seen after 72 hours of culture in 
expansion media (day 0 of 3D chondrocyte differentiation). (***p< 0.001. n = 8). 
*** *** 
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Figure 5-36: Runx2 mRNA expression during chondrocyte hypertrophic differentiation 
on PLLA/calcium phosphate scaffolds,  relative to the runx2 mRNA expression level seen 
after 72 hours of culture in expansion media (day 0 of 3D chondrocyte differentiation). 
(*p< 0.05. n = 8). 
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Figure 5-37: Runx2 mRNA expression in the chondrocytes during hypertrophic 
differentiation culture on PLLA/calcium phosphate scaffolds compared to expression 
seen on the PGA scaffold material. The data is normalised to the gene expression 
observed at passage 2 on tissue culture plastic (2D culture). (n = 8) 
* 
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5.5 Cranial Implantation of Hypertrophic Constructs Cultured on PGA 
5.5.1 Construct Decellularisation 
PGA constructs were decellularised by washing the constructs with varying numbers of 
hypertonic and ionic buffer cycles (Section 4.2.6). After 2 cycles a significant decrease 
in genetic material was seen with an average of 79.68% DNA removal obtained. The 
removal of DNA was not significantly increased by the addition of another a cycle of 
washing with hypertonic and ionic buffers (Figure 5-38). The removal of genetic 
material is also confirmed by DAPI staining (Figure 5-38) Two cycles of washing with 
hypertonic and ionic buffers also did not have a significant effect on the percentage of 
GAG removed from the ECM of the constructs when compared to 1 cycle, whereas 3 
cycles was shown to significantly increase the amount of GAG removed from the 
constructs (Figure 5-40).  
 




















Figure 5-38: The percentage DNA removal after cycles of washing the constructs 
cultured on PGA with SDS and ionic buffers (* p<0.05, n=3  
* 
* 




Figure 5-39: DAPI staining illustrating the removal of genetic material from 
hypertrophic constructs cultured on PGA after (B) 1 cycle, (C) 2 cycles and (D) 3 cycles of 































Figure 5-40: The percentage loss of GAG from the constructs cultured on PGA after 
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5.5.2 Constructs Pre-Implantation 
5.5.2.1 ‘Living’ Constructs  
Before implantation, constructs were shown to stain positively for the markers of 
hypertrophy, collagen type X (Figure 5-41(E)) and alkaline phosphatase (Figure 
5-41(D)). They were also shown to contain chondrocytes with a large cellular 
morphology (Figure 5-41(A)) and had a high GAG content (Figure 5-41 (B, C)). The 
constructs were also shown to be negative for alizarin red staining and therefore there 
was no mineralisation of the constructs before implantation into the defect.  
 
Figure 5-41: Immunohistochemical and histological staining of the PGA constructs 
before implantation into the cranial defect model. (A) haematoxylin and eosin stain; (B) 
toluidine blue; (C) alcian blue; (D) alkaline phosphatase; (E) collagen type X; (F) alizarin 
red. Insert micrographs show non-specific staining. Scale bars = 100µm. 
PhD Thesis                                                                                                               Bardsley 2014 
100 
 
5.5.2.2 Decellularised Constructs 
An average of 79.68 % DNA removal was achieved during the decellularisation process 
(Figure 5-38), this removal of genetic material could be visualised by the decrease in 
DAPI staining shown in Figure 5-42 after the grafts underwent the decellularisation 
protocol.   
 
Figure 5-42: DAPI staining illustrating the decellularisation of the PGA constructs before 
implantation into the cranial defect. (A) Construct before decellularisation; (B) construct 
post decellularisation (magnification x5).  
The decellularisation protocol led to a 10.18 % decrease in GAG content in the ECM 
and this can be seen in the lower intensity of both toluidine blue (Figure 5-43(B)) and 
alcian blue (Figure 5-43(C))staining in the decellularised construct a when compared to 
the ‘living’ constructs (Figure 5.37). Staining for collagen type X was also decreased in 
the decellularised constructs (Figure 5-43(E)) compared to the ‘living’ constructs. The 
lack of staining by Alizarin red again showed that there was no mineralisation of the 








Figure 5-43: Immunohistochemical and histological staining of decellularised PGA 
constructs before implantation into the cranial defect. (A) haematoxylin and eosin 
stain; (B) toluidine blue; (C) alcian blue; (D) alkaline phosphatase; (E) collagen type X; 
(F) alizarin red. Insert micrographs show non-specific staining. Scale bars = 100 µm. 
5.5.2.3 BM-MSC Recellularised Constructs 
BM-MSCs were characterised to assess their differentiation multipotentiality before 
being used for construct recellularisation. Chondrogenic, osteogenic and adipogenic 
differentiation was achieved from the BM-MSCs derived from rat femurs (Figure 5-44) 
using well-described, classical differentiation protocols. Once characterised and seeded 
on to the decellularised constructs, DAPI staining showed that the BM-MSCs were able 
to attach and penetrate into the decellularised constructs (Figure 5-45). 
 




Figure 5-44: Staining to show the differentiation capacities of rat BM-MSCs. (B) Alcian 
blue staining to show proteoglycan-rich extracellular matrix of micromass cultures of 
MSCs cultured under conditions to induce chondrogenic differentiation (control (A)); (D) 
Alizarin red staining to show mineralisation in MSCs cultured under conditions to induce 
osteogenesis (control (C)); (F) oil red O staining of lipid vesicles in MSCs cultured under 















Figure 5-45: DAPI staining showing the attachment and penetration of BM-MSCs into 
the decellularised PGA constructs.(A) brightfield image of the decellularised construct, 
(B) DAPI image showing the penetration of the BM-MSC into the   
5.5.3 Repair of Cranial Defects 4 Weeks after Implantation 
After 4 weeks of implantation, a small amount of bone formation, indicative of defect 
healing was observed using microCT.  Some mineralisation was evident in all defects 
implanted with constructs with little apparent bone formation in the empty defects 
(Figure 5-46). Further analysis showed that the average percentage bone volume in the 
defect treated with the ‘living’ graft, decellularised graft and MSC recellularised graft 
was 15.15 %, 19.91 % and 14.10 % therefore all grafts showed an increased healing 
compared to the empty defects where percentage bone volume in these defects was 
7.60 % (Figure 5-47). While these increases were not significant it suggested that the 
grafts may have enhanced better healing (i.e. bone formation) at later time periods. 
Histological analysis of the defects showed that vascularisation of both the ‘living’ and 
decellularised grafts had occurred by week 4. The decellularised graft also shows some 
bone formation within the defect as highlighted by the arrow (Figure 5-48). The alcian 
blue staining shows a decrease in ECM, highlighted by a decrease in GAG, around the 
invading blood vessels (Figure 5-49)  
A B 




Figure 5-46: MicroCT analysis of the cranial bone defects 4 weeks after  implantation of 
either ‘living’, decellularised and BM-MSC recellularised PGA constructs compared to 
the control ‘empty’ defects. (n=3 animals/construct group) 
 












































































Figure 5-47: Percentage bone volume in the empty defect compared to the repair seen 
using ‘living’, decellularised and MSC recellularised PGA constructs 4 weeks after 









Figure 5-48: Haematoxylin and eosin staining of cranial defects 4 weeks after implantation with either a ‘living’ PGA construct, 
decellularised PGA construct, decellularised PGA construct re-seeded with BM-MSCs or left unfilled. The arrow highlights the initial 
bone formation in the decellularised PGA construct. Magnifications are x4 (upper 4 images), x10 (middle 4 images) and x20 (bottom 4 
images). Scale bars = 500 µm (upper 4 images), 200 µm (middle 4 images) and 100 µm (bottom 4 images). (n=3 animals/construct 
group) 
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Figure 5-49: Alcian blue staining of cranial defects to show localisation of the glycosaminoglycans in the defects. 4 weeks after 
implantation with either a ‘living’ PGA construct, decellularised PGA construct, decellularised PGA construct re-seeded with BM-MSCs 
or left unfilled. Magnifications are x4 (upper 4 images), x10 (middle 4 images) and x20 (bottom 4 images). Scale bars = 500 µm (upper 
4 images), 200 µm (middle 4 images) and 100 µm (bottom 4 images). (n=3 animals/construct group) 
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5.5.4 Repair of Cranial Defects 8 Weeks after Implantation 
After 8 weeks of implantation, two of the ‘living’ constructs visibly showed the ability 
to significantly heal the defects (i.e. stimulate bone formation) when compared to the 
empty defects (Figure 5-50). The average percentage bone volume was significantly 
higher when a ‘living’ construct (22.94 %) was implanted compared to an average 
healing in the empty defect (7.07 %) (Figure 5-55). The decellularised constructs also 
gave a significant increase in bone healing both visually by microCT (Figure 5-50) and 
through percentage bone volume analysis (Figure 5-51) where a 30.73 % bone healing 
was observed. Bone regeneration using the decellularised constructs was greater than 
that of the ‘living’ constructs. However, this increase was not significant. A smaller 
increase in bone formation was observed with the BM-MSC recellularised constructs 
(Figure 5-50). However, the average percentage increase in bone volume of 18.29 % 
was not found to be significantly different when compared to that of the empty defect 
(Figure 5-51). 
Histological analysis of the defects showed that bone regeneration was occurring 
throughout both the ‘living’ and decellularised grafts. The BM-MSC recellularised 
construct, however, did not show signs of being remodelled into bone (Figure 5-52). 
Alcian blue staining of the defects showed a decrease in ECM in both the ‘living’ and 
BM-MSC recellularised constructs as the Hypertrophic cartilage ECM is degraded, as 
represented by low intensity staining indicating a decrease in GAG (Figure 5-53).  
 




Figure 5-50: MicroCT analysis of cranial defects after 8 weeks of implantation of either 
‘living’, decellularised or BM-MSC recellularised hypertrophic constructs cultured on 
PGA compared to the empty (control) defects. (n=3 animals/construct group) 












































































Figure 5-51: Percentage bone volume in the empty defect compared to the repair seen 
using ‘living’, decellularised and BM-MSC recellularised hypertrophic constructs 








Figure 5-52: Haematoxylin and eosin staining of defects 8 weeks after implantation with either a ‘living’ PGA construct, decellularised 
PGA construct, decellularised PGA construct re-seeded with BM-MSCs or left unfilled. Magnifications are x4 (upper 4 images), x10 
(middle 4 images) and x20 (bottom 4 images). Scale bars = 500 µm (upper 4 images), 200 µm (middle 4 images) and 100 µm (bottom 
4 images). (n=3 animals/construct group) 




Figure 5-53: : Alcian blue staining of cranial defects to show localisation of the glycosaminoglycans 8 weeks after implantation with 
either a ‘living’ PGA construct, decellularised PGA construct, decellularised PGA construct re-seeded with BM-MSCs or left unfilled. 
Magnifications are x4 (upper 4 images), x10 (middle 4 images) and x20 (bottom 4 images). Scale bars = 500 µm (upper 4 images), 200 
µm (middle 4 images) and 100 µm (bottom 4 images). (n=3 animals/construct group) 
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5.5.5 Repair of Cranial Defects 12 Weeks after Implantation 
Visual assessment of microCT images showed a higher degree of bone healing with all 
construct types compared to that of the empty defect (Figure 5-54). Significant 
increases in percentage bone volume were observed when using both ‘living’ grafts 
(38.48 %) and decellularised grafts (38.59 %) when compared to the empty graft (7.56 
%) (Figure 5-55). There was no significant difference in bone formation between the 
‘living’ and decellularised constructs. BM- MSC recellularised constructs showed a 
percentage bone volume of 21.22 % which was not significant when compared to the 
empty defects (Figure 5-55).  
 
Figure 5-54:  MicroCT images of the cranial defects after 12 weeks of implantation of 
either ‘living’, decellularised or BM-MSC recellularised hypertrophic constructs cultured 
on PGA compared to the empty (control) defects. (n=3 animals/construct group) 













































































Figure 5-55: Percentage bone volume in the empty defect compared to the repair seen 
using ‘living’, decellularised and MSC recellularised hypertrophic constructs cultured on 
PGA after 12 weeks after implantation. (** p<0.01. n=3 animals/construct group). 
 
Histological analysis of the defects showed continued bone regeneration in the ‘living’ 
and decellularised grafts, however, at week 12 there is also some evidence of bone 
regeneration in the BM-MSC recellularised graft (Figure 5-56). More intense alcian blue 
staining is observed in the areas of new bone regeneration (Figure 5-57).  
** 
** 




Figure 5-56: Haematoxylin and eosin staining of cranial defects 12 weeks after implantation with either a ‘living’ PGA construct, 
decellularised PGA construct, decellularised PGA construct re-seeded with BM-MSCs or left unfilled. Magnifications are x4 (upper 4 
images),, x10 (middle 4 images)  and x20 (bottom 4 images). Scale bars = 500 µm (upper 4 images), 200 µm (middle 4 images) and 
100 µm (bottom 4 images). (n=3 animals/construct group) 




Figure 5-57: Alcian blue staining of cranial defects 12 weeks after implantation to show localisation of the glycosaminoglycans 12 
weeks after implantation with either a ‘living’ PGA construct, decellularised PGA construct, decellularised PGA construct re-seeded 
with BM-MSCs or left unfilled. Magnifications are x4 (upper 4 images), x10 (middle 4 images) and x20 (bottom 4 images). Scale bars 
= 500 µm (upper 4 images), 200 µm (middle 4 images) and 100 µm (bottom 4 images). (n=3 animals/construct group) 
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5.5.6  Healing Over a 12 Week Period 
‘Living’ and decellularised constructs were shown to significantly increase the 
percentage bone volume within the cranial defect over the 12 week implantation 
(Figure 5-58 and Figure 5-59  respectively). While an increase in percentage bone 
volume was observed when using a BM-MSC recellularised construct this increase was 



























Figure 5-58: Increase in the percentage bone volume in cranial defects implanted with a 
‘living’ hypertrophic construct cultured on PGA over a 12 week period  following 
implantation (p**<0.01. n=3 animals/time point) 
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Figure 5-59: Increase in the percentage bone volume in cranial defects implanted with a 
decellularised hypertrophic construct cultured on PGA over a 12 week period following 



























Figure 5-60: Increase in the percentage bone volume increase in cranial defects 
implanted with BM-MSC recellularised hypertrophic construct cultured on PGA over a 
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5.6 The Effect of Bioreactor Culture on Hypertrophic Differentiation 
The amount of GAG accumulation by the PLLA/calcium phosphate constructs varied 
significantly depending on the culture conditions utilised (Figure 5-61). A significant 
increase in the GAG accumulation in the ECM was observed by day 28 when the 
constructs were cultured utilising semi-static culture conditions compared to 
constructs cultured under static conditions. The accumulation of GAG into the ECM 
was the greatest at all time points when the constructs were cultured in the perfusion 
bioreactor compared to the semi-static or static conditions (Figure 5-61). The 
constructs incubated in the bioreactor contained 49.81 % GAG within their ECM 
compared to GAG levels of 14.10 %  in the ECM of constructs cultured under semi-
static conditions and 1.54 % in the ECM of constructs cultured under static conditions.  
Histological and immunohistochemical analysis illustrated a lack of hypertrophic 
differentiation in constructs cultured under static conditions. This was indicated by the 
absence of collagen type X and alkaline phosphatase expression in the constructs. 
Alcian blue and toluidine blue staining (indicative of proteoglycan formation) was 
present but at a low intensity. Collagen type II expression was also conserved under 
static conditions (Figure 5-62). However, both the semi-static and bioreactor conditions 
enabled full hypertrophic differentiation of the chondrocytes after 42 days of culture. 
This was confirmed by the chondrocytes developing a larger cell morphology, typical of 
hypertrophic chondrocytes, and expressing collagen type X and alkaline phosphatase 
(Figure 5-62). 
 
Analysing the constructs for mRNA expression showed that all of the culture conditions 
resulted in downregulation of collagen type II and by day 42 there was no significant 
difference in the collagen type II gene expression between the culture conditions 
(Figure 5-64). Collagen type X and alkaline phosphatase gene expression was not 
significantly upregulated during static culture and the expression of these proteins 
remained at a low level (Figure 5-65 and Figure 5-66 respectively). The low level of 
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collagen type X and alkaline phosphatase gene expression corresponded to the low 
levels of hypertrophic differentiation seen in the constructs incubated under static 
conditions (Figure 5-62). The semi-static conditions and the bioreactor gave constructs 
similar levels of collagen type X upregulation throughout the 42 day culture period 
(Figure 5-65). However the use of the semi-static conditions resulted in higher gene 
expression for alkaline phosphatase and denser staining for the enzyme in the 










































Figure 5-61: Percentage GAG accumulation within the ECM of hypertrophic constructs 
cultured on the PLLA/calcium phosphate scaffold material at day 14, 28 and 42 under 











Figure 5-62: Histological analysis of PLLA/calcium phosphate constructs cultured under static, semi-static and bioreactor culture 
conditions. Insert micrographs show non-specific staining. Scale bars = 100µm. (representative images n=6) 





Figure 5-63: Immunohistochemical analysis of PLLA/calcium phosphate constructs cultured under static, semi-static and bioreactor 
culture conditions. Insert micrographs show non-specific staining. Scale bars = 100µm. (representative images n=6) 















































Figure 5-64: Comparison of the effect of static, semi-static and bioreactor culture 
conditions on collagen type II mRNA expression during a 42 day incubation period. The 
data is normalised to the gene expression observed after 72 hours on culture in 
expansion media on the PLLA/calcium phosphate scaffold materials (D0 of 3D 

















































Figure 5-65: Comparison of the effect of static, semi-static and bioreactor culture 
conditions on collagen type X mRNA expression during a 42 day incubation. The data is 
normalised to the gene expression observed after 72 hours on culture in expansion 
media on the PLLA/calcium phosphate scaffold materials (D0 of 3D chondrocyte 






























































Figure 5-66: Comparison of the effect of static, semi-static and bioreactor culture 
conditions on alkaline phosphatase mRNA expression during a 42 day differentiation 
period. The data is normalised to the gene expression observed after 72 hours on 
culture in expansion media on the PLLA/calcium phosphate scaffold materials (D0 of 3D 
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5.7 Serum-Free media 
Three serum-free media (Table 5-3) were assessed for their ability to not only support 
chondrocyte growth and survival but also to support hypertrophic differentiation.  
Table 5-3: Composition of the three serum-free media and serum-containing media 
tested for chondrocyte survival, growth and hypertrophic differentiation. 
 
Media composition 
Media 1 Basic media with 1 mg.mL
-1 BSA, 1 µg.mL-1 insulin and 50 µg.mL-
1 ascorbic acid 
Media 2 
Basic media with 1 mg.mL-1 BSA, 100 μL.mL-1 10X ITS (1.0 
mg.mL-1 recombinant human insulin, 0.55 mg.mL-1 human 
transferrin (substantially iron-free), 0.5 μg.mL-1 sodium selenite, 
470 μg.mL-1 linoleic acid, 470 μg.mL oleic acid and 50 mg.mL-1 
bovine FCS albumin) and 50 µg.mL-1 ascorbic acid 
Media 3 
Basic media with 1 mg.mL-1 BSA, 100 μl.mL-1 10X ITS (1.0 mg.mL-
1 recombinant human insulin, 0.55 mg.mL-1 human transferrin 
(substantially iron-free), 0.5 μg.mL-1 sodium selenite, 470 μg.mL-
1 linoleic acid, 470 μg.mL-1 oleic acid and 50 mg.mL-1 bovine FCS 
albumin), 50 µg.mL-1 ascorbic acid and 1 nM thyroxine 
Serum-containing 
media  
Basic media with 10% FCS, 1 µg.mL-1 insulin and 50 µg.mL-1 
ascorbic acid 
 
Serum-free media 1 was shown to produce constructs with a significantly lower GAG 
content (1.94 % of ECM dry weight) than constructs cultured in serum-free media 2 
(15.94 % of ECM dry weight), serum-free media 3 (19.44 % of ECM dry weight) and 
serum-containing media used in previous experiments (12.91 % of ECM dry weight) 
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(Section 5.3) (Figure 5-67). No significant difference was seen between serum-free 































Figure 5-67: The percentage GAG concentration present in the PGA constructs  cultured 
in three serum-free media compared to the serum-containing media. (* p<0.05, ** 
p<0.01. n=9) 
Serum-free media 1 produced grafts with a low level toluidine blue (Figure 5-68(B)) and 
alcian blue (Figure 5-68(C)) confirming that the quality of the ECM was poor with a low 
GAG concentration. Chondrocytes with a large cellular morphology can be seen in 
within the constructs (Figure 5-68(A)). However, chondrocytes in these constructs did 
not produce alkaline phosphatase (Figure 5-68(D)) or collagen type X (Figure 5-68(F)). 
Serum-free media 2 was shown to produce chondrocytes with a large cellular 
morphology (Figure 5-69(A)) and good quality ECM with dense staining for toluidine 
blue (Figure 5-69(B) and alcian blue (Figure 5-69(C)). The grafts were also shown to 
express collagen type X (Figure 5-69(F)) and alkaline phosphatase (Figure 5-69(D)) 
showing that cell proliferation and hypertrophic differentiation were supported by 
serum-free media 2. 
This level of hypertrophic differentiation and chondrocyte proliferation was also 
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phosphatase was more intense when using this media 3 compared to serum-free 
media 2 (Figure 5-70(D)). 
 
Figure 5-68: Representative histological and immunohistochemical analysis of rat nasal 
chondrocyte constructs after 42 days culture on PGA in serum-free media 1. (A) 
Haematoxylin and Eosin Stain; (B) Toluidine Blue; (C) Alcian Blue; (D) Alkaline 
Phosphatase; (E) Collagen II; (F) Collagen X. Insert micrographs show non-specific 










Figure 5-69: Representative histological and immunohistochemical analysis of rat nasal 
chondrocyte constructs after 42 days culture on PGA in serum-free media 2. (A) 
Haematoxylin and Eosin Stain; (B) Toluidine Blue; (C) Alcian Blue; (D) Alkaline 
Phosphatase; (E) Collagen II; (F) Collagen X. Insert micrographs show non-specific 











Figure 5-70: Representative histological and immunohistochemical analysis of rat nasal 
chondrocyte constructs after 42 days culture on PGA in serum-free media 3. (A) 
Haematoxylin and Eosin Stain; (B) Toluidine Blue; (C) Alcian Blue; (D) Alkaline 
Phosphatase; (E) Collagen II; (F) Collagen X. Insert micrographs show non-specific 
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Gene expression analysis illustrated that serum-free media 2 caused the 
downregulation of collagen type II however that serum media allows for a significantly 
higher decrease in expression at day 42. Collagen type X expression was significantly 
increased at day 42 however this increase occurred at a later stage of culture. Alkaline 
phosphatase levels were comparable to those seen when using the serum media.  
Media 3 also allowed for the downregulation of collagen type II although once again at 
a significantly lower level than the serum media. Collagen type X significantly higher at 
d 28 but comparable at day 42. Alkaline phosphatase expression was significantly 
higher at day 42, which is in agreement with the more intense alkaline phosphatase 



















































Figure 5-71: Collagen type II mRNA expression of the chondrocytes throughout the 42 
day culture period on PGA. Showing the effect of serum-free media 2 and serum-free 
media 3 compared to serum media on the expression of collagen type II within the 
grafts. The data is normalised to the gene expression observed after 72 hours on culture 
in expansion media on the PLLA/calcium phosphate scaffold materials (D0 of 3D 
chondrocyte differentiation.  (* p<0.05, n=6) 
* 
* 












































Figure 5-72 : Collagen type X mRNA expression of chondrocytes throughout the 42 day 
culture period on PGA. Showing the effect of serum-free media 2 and serum-free media 
3 compared to serum media on the expression of collagen type II within the grafts. The 
data is normalised to the gene expression observed after 72 hours on culture in 
expansion media on the PLLA/calcium phosphate scaffold materials (D0 of 3D 
























































Figure 5-73: Alkaline phosphatase mRNA expression of chondrocytes throughout the 42 
day culture period on PGA. Showing the effect of serum-free media 2 and serum-free 
media 3 compared to serum-containing media on the expression of collagen type II 
within the grafts. The data is normalised to the gene expression observed after 72 hours 
on culture in expansion media on the PLLA/calcium phosphate scaffold materials (D0 of 









The repair of large bone defects is still a major challenge for surgeons, and the current 
‘gold standard’ (autologous bone transplant) while effective has complications such as 
the possibility of donor site pain and infection, and a low limited volume of bone 
available for transplant. Therefore tissue-engineering has been investigated for the 
production of bone grafts that are capable of promoting tissue regeneration. 
The majority of bone tissue-engineering research, as discussed in the literature review, 
has been directed towards the differentiation of stem cells into osteoblasts to produce 
bone tissue, therefore mimicking the intramembranous ossification pathway. This 
differentiation technique, however, has several drawbacks for clinical applications. 
Osteoblasts and the resulting bone tissue require high nutrient exchange rates and 
oxygen levels within the tissue and because of these requirements, cannot withstand 
the hypoxic conditions usually found in a wound bed.  The use of the endochondral 
pathway for producing bone grafts may have significant potential as the hypertrophic 
chondrocytes can survive the lower oxygen and nutrient environments present at the 
site graft site and provide growth factors which will promote vascularisation, graft 
integration and bone regeneration.  
To date there has been little research directed at the potential of tissue engineering 
hypertrophic cartilage as bone graft substitute. Research published by Scotti et al 
investigating this tissue-engineering approach used BM-MSCs (Scotti et al., 2010). 
However, the use of BM-MSCs as a cell source for tissue-engineering has 
disadvantages. As with bone grafting, bone marrow biopsies may result in long-term 
post-operative pain and older patients have less proliferative and viable BM-MSCs 
which may fail to differentiate. Therefore, in this study, chondrocytes were isolated 
from the nasal septum. The nasal septum was used as it represents a potential clinically 
relevant biopsy site which should have less morbidity than bone grafts or bone marrow 
biopsies. Nasal chondrocytes were relatively easy to isolate and proliferated well in 
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vitro. Previous work by Kwarciak in this laboratory has showed that nasal chondrocytes 
were able to differentiate into hypertrophic chondrocytes in vitro and formed 
mineralised cartilage matrix once implanted subcutaneously in vivo (Kwarciak, 2009).  
The research presented in this thesis has investigated different scaffold materials in 
order to produce larger constructs, as well as investigating the hypertrophic 
differentiation of nasal chondrocytes through exploration of gene expression and 
extracellular matrix protein deposition. The potential of these hypertrophic cartilage 
constructs to regenerate bone tissue in a cranial defect in vivo has also been 
investigated. Preliminary studies into the use of bioreactor culture and serum-free 
media have also been performed in order to make translation of this research to the 
clinic more likely. 
6.1 Scaffold Fabrication 
As discussed in section 2.5.2, poly(hydroxyorthoesters) such as PGA and PLLA have 
been used as scaffolds in tissue-engineering due to the availability, biocompatibility 
and processibility of these materials (Moran et al., 2003). These materials have also 
gained regulatory approval, which makes them advantageous for investigation. PLLA 
does have the advantage of a lower degradation rate  (Tsai et al., 2006) which will 
allow for the formation of a more robust construct which will retain both size and 
shape, this may become important when looking at the production of customised 
grafts for facial reconstruction. Therefore, electrospun random-fibre PLLA scaffold was 
compared to a commercial non-woven PGA scaffold material for their ability to drive 
hypertrophic chondrocyte differentiation. 
Calcium phosphates are also regularly used in bone tissue-engineering (Section 2.5.2) 
as it is an osteoconductive material, which is biocompatible with minimal 
immunological, toxicity or foreign body effects (Burg et al., 2000). Calcium phosphates 
also have the ability to bind directly to the bone and therefore enable continuous 
tissue healing (LeGeros, 2002).  A modified PLLA/calcium phosphate composite scaffold 
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material was therefore also fabricated for this study to investigate its potential as a 
scaffold material for hypertrophic cartilage tissue-engineering. 
A composite scaffold was produced which XRD showed contained two phases of 
calcium phosphate, brushite and hydroxyapatite, both of which are currently used in 
bone cements (Grover et al., 2003). Hydroxyapatite is the main calcium phosphate 
seen within bone itself, making up around 90% of bone mineral (Lichte et al., 2011). 
During endochondral ossification, hydroxyapatite is the mineral initially laid down in 
the calcifying cartilage matrix (Mackie et al., 2008). Brushite has also been shown to be 
present within the calcifying cartilage matrix, although less abundant than 
hydroxyapatite (Rey et al., 1991). Brushite also has the ability to be converted into 
hydroxyapatite in vivo over time, through dissolution in low pH and re-precipitation as 
hydroxyapatite (Grover et al., 2003). The PLLA/calcium phosphate scaffold material 
fabricated for this study should therefore, mimic the natural environment of 
hypertrophic chondrocytes within the growth plate as well as being more osteogenic 
than the plain PLLA and PGA scaffolds.  
Differences in hydrophilicity of the scaffolds were observed through contact angle 
measurements with the PLLA scaffold material being hydrophobic and the 
PLLA/calcium phosphate scaffold being more hydrophilic (Table 5-1). Chen et al 
discovered that apatite coated PLLA surfaces were more hydrophilic than non-coated 
PLLA, allowing for a flatter attached chondrocyte morphology and therefore, a better 
adhesion to the polymer/ceramic composite (Chen et al., 2008). The commercial PGA 
scaffold material was also observed to be more hydrophilic than the PLLA scaffold 
material. The differences seen in hydrophilicity will have an effect on protein 
adsorption and therefore the ability of the chondrocytes to adhere to the biomaterials. 
Both PGA and PLLA have been shown to adsorb proteins, however the increased rate 
of hydrolysis of PGA has been shown to increase the rate of protein adsorption to the 
polymer surface (Atthoff and Hilborn, 2007). The addition of the calcium phosphate 
dramatically alters the contact angle making the scaffold highly hydrophilic. Highly 
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hydrophilic biomaterials have been shown to expel proteins and inhibit protein 
adsorption. The calcium phosphate, however, is known to be bioactive and is able to 
adsorb proteins, this bioactivity may be able to overcome the inhibition seen by 
hydrophilic surface (Wang et al., 2012).   
6.2 The Effect of FCS on Chondrocyte Hypertrophy 
It is a well-known fact that the FCS used during in vitro cell culture has a significant 
effect on cell proliferation; however, in this study it was important to investigate the 
effect of various batches FCS on the hypertrophic differentiation of chondrocytes to 
see if the sera influenced this process. 
The FCS batches tested for cell culture had a significant effect on the production of 
GAG within the ECM (Figure 5-6) as well as the hypertrophic differentiation of the 
chondrocytes (Figure 5-7). Different batches of FCS therefore supported different 
aspects of chondrocyte survival and development. This was highlighted by FCS 1 which 
gave a comparatively high level of GAG in the extracellular matrix while the 
hypertrophic differentiation of the chondrocytes was either not promoted or inhibited. 
In contrast, use of FCS 4 produced constructs with a lower GAG incorporation but 
enabled/promoted hypertrophic differentiation. The differences shown in the effects 
of the FCS batches on the extracellular matrix composition of the constructs was due to 
the variability of protein and growth factor composition of each batch of FCS (Honn et 
al., 1975). 
FCS contains a cocktail of serum proteins and bioactive agents, including growth 
factors, hormones, enzymes, vitamins and trace elements, which are essential for cell 
attachment and survival (Brunner et al., 2010), making FCS a vital addition to in vitro 
cell culture media. FCS batches, however, contain different concentrations of these 
proteins which can make the culture of cells variable (Brunner et al., 2010). 
Proteins present in FCS, which affect the proliferation and differentiation of 
chondrocytes include growth factors, such as fibroblast growth factor (FGF), insulin-like 
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growth factor 1 (IGF-1), endothelial growth factor (EGF) and transforming growth 
factor-β (TGFβ) (Olney et al., 2004), and hormones, such as insulin and thyroid 
hormones.  
The FGF family of growth factors is important in chondrocyte growth and 
differentiation with FGF-1,-2,-18 all have been shown to stimulate chondrocyte 
proliferation (Olney et al., 2004). FGF-2 (bFGF) in particular can inhibit the hypertrophic 
differentiation of chondrocytes in a dose dependent manner (Kato and Iwamoto, 
1990). Therefore, FCS with a high concentration of FGF-2 will cause the chondrocytes 
to maintain a hyaline phenotype, producing collagen type II. 
TGF-β1 has been shown to stabilise pre-hypertrophic chondrocyte morphology  
enabling the expression of collagen type II (Ballock et al., 1993). TGF-β1 inhibited 
chondrocyte hypertrophy in a dose dependent manner through activation of the 
PTHrP/Ihh pathway (Pateder et al., 2000). This activation results in an increase in PTHrP 
expression which maintains the proliferative, hyaline chondrocyte phenotype, 
inhibiting terminal differentiation and decreasing collagen type X expression (Pateder 
et al., 2000, Ferguson et al., 2000).   
IGF-1 is an important stimulator of chondrocyte proliferation (Olney et al., 2004) and 
has been shown to initiate a morphological increase in cellular volume of the 
chondrocytes (Bohme et al., 1992a). EGF, also present in the FCS, reduced the 
synthesis of IGF-1 and therefore, the proliferation and differentiation of the 
chondrocytes (Chan and Wong, 2000). Insulin can be used as an alternative to IGF as it 
has the ability to bind to both insulin receptor and IGF-I receptor (Ballock and Reddi, 
1994) and promotes the morphological increase in the cellular volume of the 
chondrocytes as well as being mitogenic (Bohme et al., 1992a). Insulin was added to 
the differentiation media and therefore, IGF and insulin concentrations within the FCS 
were unlikely to dramatically affect chondrocyte proliferation or differentiation.  
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Thyroid hormones, triiodothyronine and thyroxine, are components of the of the 
growth hormone-insulin axis and increase cellular metabolism (Mello and Tuan, 2006). 
Thyroid hormones have been shown to be strong initiators of chondrocyte hypertrophy 
when present at a concentration similar to that found in plasma and can create linearly 
organised chondrocytes while increasing the production of collagen type X and alkaline 
phosphatase in serum-free conditions (Bohme et al., 1992b, Ballock and Reddi, 1994, 
Robson et al., 2000, Okubo and Reddi, 2003, Bohme et al., 1992a). It is therefore 
suggested that thyroxine may be an important factor in FCS responsible for the 
terminal differentiation of chondrocytes in vitro (Ballock and Reddi, 1994).  
As discussed in Section 2.1.4 endochondral ossification is a tightly regulated process 
with requires the correct expression of growth and transcription factors in order for 
the correct hypertrophic differentiation to occur. Therefore, it was essential that batch 
tests of FCS are performed before any differentiation studies are performed. In order 
to overcome this issue of FCS variability, the development of a defined serum-free 
media would be advantageous (sections 0 and 6). 
6.3  Hypertrophic Differentiation of Chondrocytes  
Once a suitable FCS batch had been found, a comparison of the experimental 
electrospun PLLA and modified PLLA/calcium phosphate scaffolds fabricated in section 
5.1 and a commercial PGA scaffold obtained from Cellon was undertaken.  
Initial studies showed that attachment on the more hydrophilic surfaces, PGA and 
PLLA/calcium phosphate scaffolds was significantly increased when compared to the 
more hydrophobic electrospun PLLA.  Moran et al showed that chondrocytes attached 
to hydrophilic surfaces, such as PGA, had a flat morphology with several projections 
attached to the polymer fibres, whereas chondrocytes seeded on PLLA had a spherical 
morphology (Moran et al., 2003). The flat morphology of chondrocytes on the scaffold 
allowed both increased cell attachment and also, retention of cells on the scaffold 
during semi-static culture due to the high surface area cell contact to the polymer and 
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the high number of projections securing the cells to the polymer fibres (Papadaki et al., 
2001).  
The use of the electrospun PLLA scaffold not only decreased initial cell attachment but 
the construct produced after 42 days was poor in quality, with significantly lower GAG 
incorporation within the ECM (0.28 % of the dry weight of the ECM ) compared to both 
the PGA and PLLA/calcium phosphate scaffold materials (Figure 5-11). Areas of 
hypertrophic differentiation, containing chondrocytes with a large cellular volume, 
with co-localised expression of collagen type X, were observed within these constructs. 
Alkaline phosphatase, however, was not expressed in chondrocytes differentiated on 
the PLLA scaffold material. This significant decrease in PLLA construct quality can be 
attributed to the hydrophobic nature of the PLLA, as it was observed that the 
chondrocytes will attach with a rounded morphology. This morphology will not only 
affect the retention of the chondrocytes during semi-static culture, but has also been 
shown to decrease cellular proliferation on the scaffold material (Singhvi et al., 1994, 
Moran et al., 2003). 
Both the PGA and PLLA/calcium phosphate scaffold materials enabled chondrocyte 
attachment) and proliferation and also hypertrophic differentiation of nasal 
chondrocytes after 42 days in differentiation media in a semi-static environment. 
Constructs expressed both collagen type X and alkaline phosphatase which are 
characteristic markers of hypertrophy and are co-located with hypertrophic 
chondrocytes in the growth plate during endochondral ossification. Chondrocytes in 
the constructs also exhibited an increase in cell volume, adopting the large cellular 
morphology which is typical of hypertrophic chondrocytes. Culture on the PGA and 
PLLA/calcium phosphate scaffold materials also enabled the accumulation of GAG in 
the ECM (indicative of the level of proteoglycan content).  By day 42 the constructs had 
accumulated GAG levels (as a percentage of ECM dry weight) of 12.91 % (PGA) and 
14.10 % (PLLA/calcium phosphate) (Figure 5-11). A significantly quicker production and 
incorporation of GAG in the ECM occurred on the PLLA/calcium phosphate constructs 
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when compared to the PGA constructs in the initial stages of culture. However, by day 
42 the percentage GAG in the ECM of the PLLA/calcium phosphate constructs were not 
significantly higher than that seen in the PGA scaffold material (Figure 5-12).  
While the production of an engineered tissue with all characteristics of hypertrophic 
cartilage was successful in vitro on both the PGA and PLLA/calcium phosphate scaffold 
materials these constructs failed to mineralise in vitro. There are several hypotheses as 
to why this occurred; either the culture conditions used in the culture were not 
conducive to further differentiation, apoptosis or mineralisation of the hypertrophic 
chondrocytes or that the addition of another cell type, endothelial cells or osteoblasts, 
was required in order to kick start mineralisation. If this graft material is to be 
potentially clinically effective, it needs to be shown to mineralise in vivo and be 
remodelled into bone. It was also hoped that this in vivo implantation may indicate on 
the reasons the constructs failed to mineralise in vitro (Section 5.5 and 6.5). 
There was also some evidence of an alignment of the hypertrophic chondrocytes 
within the constructs produced on the PLLA/calcium phosphate scaffold material. This 
alignment of hypertrophic chondrocytes is naturally found within the growth plate of 
the long bones.  Therefore, the engineered constructs were mimicking to some degree, 
the natural hypertrophic differentiation and cellular organisation of the growth plate 
hypertrophic chondrocytes. While it is not known whether this cellular organisation 
contributed to the increased expression of hypertrophic markers, it is important that 
the engineered tissue mimics the hypertrophic tissue found within the body. This 
cellular organisation may also effect the mineralisation and formation of bone when 
the grafts are placed in an in vivo environment.  
6.4 Protein and Gene Expression 
While it was shown that both the PGA and PLLA/calcium phosphate scaffold materials 
were both able to support hypertrophic differentiation, it was necessary to further 
examine the differentiation through gene and protein expression for any differences 
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between the scaffold materials. During the literature review several key ECM proteins, 
growth factors and signalling molecules were discussed for their importance in the 
endochondral ossification pathway (Section 2.1.4). It was therefore decided to 
investigate the expression of these key proteins and factors throughout chondrocyte 
differentiation on both scaffold materials.   
The differentiation of chondrocytes from a hyaline to a hypertrophic phenotype can be 
followed throughout the differentiation period and is characterised in particular, by a 
change in ECM components. During the initial differentiation period, the gene 
expression of the hyaline ECM component, collagen type II was increased. Collagen 
type II is incorporated into the ECM before giving way to the expression of 
hypertrophic ECM proteins, collagen type X and alkaline phosphatase. The signalling 
molecule, Ihh, and transcription factors, sox9 and runx2 are also vital for the regulation 
of hypertrophic differentiation during embryogenesis and long bone growth, with 
disruptions in the expression of these proteins causing dwarfism and other growth 
defects (Kronenberg, 2003).  
6.4.1 The Effect of Three Dimensional Culture on Gene Expression 
As the chondrocytes were transferred from a 2D to 3D culture system, significant 
alterations in the gene expression profile of the chondrocytes were observed (Figure 
5-14 and Figure 5-15). A decrease in expression of hypertrophic lineage genes, collagen 
type X, alkaline phosphatase and runx2 was observed on both PGA and PLLA/calcium 
phosphate scaffold materials as the chondrocytes regained their hyaline phenotype.  
Use of 3D environments for the culture of chondrocytes is important. In a 2D 
environment chondrocytes dedifferentiate; displaying a fibroblastic-like phenotype and 
expressing low levels of ECM proteins such as collagen type I. Dedifferentiation was 
reversed when the chondrocytes were placed into a 3D environment, leading to an 
increase in ECM production and an upregulation of collagen type II as the chondrocytes 
regained their hyaline phenotype.  
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An initial upregulation of collagen type II mRNA expression was observed as the cells 
were transferred a 2D environment to the PGA scaffold material (Figure 5-14), 
suggesting that the chondrocytes may have initially regained a hyaline phenotype. 
However, collagen type II mRNA expression was decreased in chondrocytes cultured on 
the PLLA/calcium phosphate scaffold (Figure 5-15).  Changes in the morphology of the 
scaffold material may account for this difference in gene expression. The PGA scaffold 
material was a highly porous material (>97%) with a large pore size which allowed for 
the infiltration of chondrocytes into the scaffold, whereas electrospun scaffolds 
typically have a smaller pore size and therefore do not allow for cellular penetration 
(Lannutti et al., 2007). Therefore, it could be assumed that the PLLA/calcium phosphate 
scaffold material will act like a mat on which the chondrocytes will proliferate. This 
may contribute to the initial decreases in collagen type II expression seen when the 
chondrocytes are seeded on to the PLLA/calcium phosphate scaffold material., 
Alternatively, the lowered collagen type II expression may have resulted as the 
PLLA/calcium phosphate scaffolds inhibited the chondrocytes assuming an initial 
hyaline phenotype.  
The gene expression of the signalling molecule, Ihh, was increased in chondrocytes 
cultured on both scaffold materials. The gene expression of sox9 was increased on the 
PGA scaffold. Both of these agents are known to act through the PTHrP pathway to 
keep the chondrocytes in a proliferative state and inhibit hypertrophy. This 
chondrocyte proliferation is important as it is essential for the chondrocytes to multiply 
to inhabit the large surface area provided by the scaffold materials. 
This significant change in gene expression showed the importance of a 3D culture 
system for the differentiation of chondrocytes. It also suggests that the two scaffold 
materials may act differently on the hyaline and hypertrophic differentiation of the 
chondrocytes by either delaying or accelerating the different stages of differentiation. 
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6.4.2 Extracellular Matrix Gene Expression 
The collagen type II mRNA expression profile is similar on both the PGA and 
PLLA/calcium phosphate scaffold materials (Figure 5-16 and Figure 5-17 respectively). 
Collagen type II expression increases until day 7 as the cells continue to re-differentiate 
in the 3D system. It is well known that in the growth plate, the highest expression of 
collagen II is observed in resting and proliferating chondrocytes (Okeefe et al., 1994). 
Therefore, the peak of collagen II observed at day 7 can be attributed to the 
chondrocytes being in a proliferative, hyaline state. Between day 7 and day 14 there is 
a significant decrease in collagen II gene expression suggesting that the chondrocytes 
were beginning to further differentiate changing their gene expression profile from 
that of hyaline chondrocytes. Okeefe et al observed that collagen type II expression in 
the growth plate was also inhibited by high levels of collagen type X expression seen in 
the hypertrophic zone (Okeefe et al., 1994), this may explain the continued decrease in 
collagen type II expression throughout the culture until day 42. While the mRNA 
expression is strongly inhibited by day 14 immunohistochemical staining shows that 
collagen type II protein is present within the ECM throughout the culture until day 42 
(Figure 5-26 and Figure 5-28) on both scaffold materials. When looking at the growth 
plate in Figure 2-2 collagen type II is seen throughout the hypertrophic region. Collagen 
type II is degraded and removed from the ECM by collagenases, such as matrix 
metalloproteinase 13 (MMP-13) (collagenase-3) (Inada et al., 2004). MMP-13 is a 
downstream target of runx2 (Komori, 2005), which was not significantly upregulated 
until day 28 of culture (Figure 5-35) and therefore, may account for the abundance of 
collagen type II within the ECM of the constructs at day 42.  
Collagen type X is an important ECM protein for endochondral ossification expressed 
by hypertrophic chondrocytes within the growth plate (Shen, 2005). During in vitro 
culture, collagen type X gene expression was shown to significantly increase between 
day 3 and day 35 of culture on both the PGA and PLLA/calcium phosphate scaffold 
material (Figure 5-19 and Figure 5-20 respectively). Although collagen type X was 
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expressed by day 14 the protein was not incorporated within the ECM. However, by 
day 28, collagen type X protein can be detected immunochemically in the ECM of the 
construct co-located with chondrocytes with a large cellular morphology (Figure 5-26). 
This accumulation of collagen type X within the ECM is important during endochondral 
ossification as collagen type X has several essential functions while mineralisation 
occurs as well as regulating the mineralisation of ECM itself (Shen, 2005). Kirsch et al 
stated that collagen type X is essential for the binding and entrapment of matrix 
vesicles within the ECM and also allows for the influx of calcium ions into those vesicles 
(Kirsch and Wuthier, 1994). Collagen type X knockout mice were shown to have 
abnormal trabecular architectural development and produced under developed bones 
(Kwan et al., 1997, Chung et al., 1997). Expression of collagen type X peaked at day 35 
with a slight decrease seen at day 42. It is hypothesised that this decrease at day 35 
could be due to two possible mechanisms which depend on the fate of the 
chondrocytes once they have reached terminal differentiation. As discussed in Section 
2.1.4, it is generally considered that terminally differentiated chondrocytes either 
apoptose or further differentiate into chondroclasts, both of these chondrocyte fates 
will alter the gene expression profile of the chondrocytes and may possibly explain the 
decrease in collagen type X expression observed at day 42.  
Alkaline phosphatase expression was significantly upregulated during the hypertrophic 
differentiation of the nasal chondrocytes cultured on either PGA or PLLA/calcium 
phosphate scaffold materials (Figure 5-22 and Figure 5-23 respectively). Tissue-
nonspecific alkaline phosphatase has been shown to be expressed on the membranes 
of hypertrophic chondrocytes within the growth plate, with alkaline phosphatase 
knockout mice exhibiting hypomineralisation of bones (Anderson et al., 2004). There is 
a lot of debate about the role of alkaline phosphatase in the mineralisation of the 
growth plate. It was first suggested by Robison et al that alkaline phosphatase 
hydrolyses organic phosphate esters, such as inorganic pyrophosphate (PPi), to 
produce orthophosphate for incorporation into the calcium phosphate mineral 
(Robison, 1926). Another hypothesis is that it PPi inhibits mineral formation  at the site 
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of mineral crystal production (Fleisch et al., 1966) and alkaline phosphatase activity is 
required at the site of mineralisation to breakdown PPi and enable matrix 
mineralisation. It is therefore essential that alkaline phosphatase is present within the 
ECM in order for mineralisation to occur within the construct after in vivo implantation. 
It has been shown that alkaline phosphatase is present on the periphery of grafts from 
day 14 and by day 42 it is present throughout the construct (Figure 5-26).  
Gene expression of chondrocytes cultured on the PLLA/calcium phosphate scaffolds 
suggested that this scaffold maybe advantageous in supporting the hypertrophic 
differentiation of the chondrocytes, through a significant decrease in the expression of 
collagen type II and a significant upregulation of collagen type X, when compared to 
the PGA scaffold material (Figure 5-18 and Figure 5-21 respectively). An upregulation of 
alkaline phosphatase expression was also observed when using the PLLA/calcium 
phosphate scaffold material although this increase was not significant by day 42 of the 
differentiation (Figure 5-24). This change in gene expression is possibly due to the 
release of both phosphate (Pi) and calcium (Ca) ions from the calcium phosphates into 
the culture media, either due to pH associated or cellular degradation (Legeros, 1993). 
Ca ions have been shown to have an important effect on cell division and DNA 
synthesis of chondrocytes (Legeros, 1993), while Pi ions have been reported to up-
regulate the expression of genes associated with the terminal differentiation of 
chondrocytes, such as collagen type X (Coe et al., 1992, Fujita et al., 2001, Magne et al., 
2003). Ca and Pi ions have also been to shown effect the apoptosis of the chondrocytes 
once they have reached a stage of terminal differentiation and leads to extra-cellular 
matrix mineralisation (Magne et al., 2003), through the upregulation of genes, such as 
osteopontin, that are present within mineralising cell types (Magne et al., 2003, Beck 
et al., 2000).  
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6.4.3 Transcription Factor and Signalling Molecule Gene Expression 
Sox9 is one of the key fate determining transcription factors in endochondral 
ossification, with a heterozygous deletion resulted in campomelic dysplasia, a severe 
form of dwarfism affecting all cartilage and endochondral structures. Sox9 is highly 
expressed by proliferating columnar chondrocytes and acts through the PTHrP 
signalling pathway to keep the chondrocytes in a proliferative state (Hattori et al., 
2010). The expression profile of sox9 varied greatly between the two scaffold 
materials, with chondrocytes cultured on PGA dowregulating sox9 expression after an 
initial increase in sox9 expression as the chondrocytes were transferred from culture to 
the scaffolds (Figure 5-29), until day 35 when a non-significant increase was observed. 
On the PLLA/calcium phosphate scaffold material, however, the chondrocytes initially, 
downregulated sox9 gene expression as they were transferred to the scaffold from 
monolayer culture before significantly upregulating expression peaking at day 14. 
There was also a secondary non-significant peak of sox9 at day 35. These results 
suggested the chondrocytes cultured on the PLLA/calcium phosphate scaffold required 
longer to re-differentiate into a hyaline phenotype, this is also shown the initial 
decreases in collagen type II expression observed on the PLLA/calcium phosphate 
scaffold. 
This work also highlights the possibility of a secondary role for sox9 in hypertrophic 
differentiation and is illustrated by an upregulation of expression on both scaffold 
materials at day 35 of differentiation, correlating to the highest expression of both 
collagen type X and alkaline phosphatase (Figure 5-19 and 5-18 and Figure 5-22 and 5-
21 respectively). Recent work by Dy et al has shown that sox9 is also an important 
transcription factor for hypertrophic differentiation (Dy et al., 2012), where it is located 
to the nuclei of chondrocytes where it acts upon the collagen type X promoter both 
independently and through cooperation with mef2c. Sox9 also has the ability to inhibit 
the mineralisation of the hypertrophic matrix by inhibiting β-catenin signalling. 
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Therefore, the increase in sox9 gene expression seen at day 35 may hinder the 
mineralisation of the constructs in vitro. 
In the growth plate, Ihh expression is localised to the area of post-mitotic, pre-
hypertrophic chondrocytes which is adjacent to the proliferating columnar cells (Mak 
et al., 2008). It has been reported that Ihh acts through both the activation of the 
PTHrP signalling pathway (Lai and Mitchell, 2005, Kronenberg, 2003) and Ptc-1 
receptor (St-Jacques et al., 1999) which keep the chondrocytes in a proliferative state. 
(Pateder et al., 2000). However Mak et al has also suggested that Ihh also works 
independently of PTHrP to promote hypertrophic differentiation through the activation 
of the Wnt/BMP signalling pathway (Mak et al., 2008). It is therefore essential that the 
expression of Ihh occurs at the correct time within the differentiation process and is 
downregulated in the later stages of differentiation in order to allow for full 
hypertrophy to be observed. In both PGA and PLLA/calcium phosphate constructs a 
significant peak of Ihh gene expression was observed on day 21 of culture suggesting 
that the chondrocytes had undertaken a pre-hypertrophic phenotype (Figure 5-32 and 
Figure 5-33). This day 21 peak of Ihh gene expression also correlated to the decrease in 
collagen type X expression observed at day 21 in the PGA constructs (Figure 5-19). 
Therefore, Ihh may have inhibited collagen type X expression in an attempt to keep the 
chondrocytes in a proliferative state and delay the differentiation of the chondrocytes.  
Runx2 is expressed by hypertrophic chondrocytes within the endochondral growth 
plate and is essential for both promoting hypertrophic differentiation as well as 
regulating the expression of other genes associated with mineralisation and 
angiogenesis (Kim et al., 1999). The increase in expression seen during the 
differentiation of the chondrocytes is important as a heterozygous mutation leads to a 
lack of endochondral ossification in mice (Inada et al., 1999). 
Runx2 has been shown to regulate the expression of osteopontin (Sato et al., 1998), 
which is one of the main non-collagenous bone matrix proteins and is believed to allow 
the attachment of osteoclasts to the mineralised matrix and therefore, enables the 
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remodelling of the cartilage matrix (Reinholt et al., 1990). MMP-13 is also up-regulated 
by the expression of runx2 (Komori, 2005). As discussed previously, MMP-13 is vital for 
the degradation of the helical collagen type II and is highly expressed at the centres of 
ossification. (Inada et al., 2004), runx2 null mice also lacked vascularisation in mature 
hypertrophic cartilage (Inada et al., 1999, Zelzer et al., 2001), due to the repression of 
VEGF. This suggested that VEGF expression is regulated by the expression of runx2 
(Zelzer et al., 2001, Provot and Schipani, 2005). VEGF and its receptors are important in 
the regulation of angiogenesis during endochondral bone formation as well as inducing 
the migration and alkaline phosphatase activity of osteoblasts (Midy and Plouet, 1994) 
and being a chemo-attractant for osteoclasts (Engsig et al., 2000).   
Therefore, runx2 expression within the constructs suggested that the ECM of the 
constructs cultured on both the PGA and PLLA/calcium phosphate scaffold materials 
expressed all the growth factors and proteins required for mineralisation and 
vascularisation when implanted in vivo.  
Monitoring the hypertrophic differentiation of chondrocytes is important for the 
development of a tissue-engineered graft material, as it is essential to ensure that the 
cells follow the same differentiation pathway and that that pathway mimics that seen 
during the natural differentiation in the endochondral ossification growth plate. It also 
highlights the stages at which the chondrocytes are in the differentiation with the high 
expression of collagen type II suggesting a hyaline phenotype, Ihh a pre-hypertrophic 
phenotype and the expression of collagen type X, alkaline phosphatase and runx2 for 
hypertrophic chondrocytes.  
Due to the increase in hypertrophic marker expression and the high percentage GAG 
seen using the PLLA/calcium phosphate scaffold, it may be interesting to assess these 
scaffolds in vivo. As it has also been shown that both Ca and Pi ions effect the apoptosis 
of the chondrocytes once they have reached a stage of terminal differentiation and 
leads to extra-cellular matrix mineralisation (Magne et al., 2003). PLLA/calcium 
phosphate scaffolds may therefore be able to increase bone healing and mineralisation 
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when compared to grafts grown on the PGA scaffold material. However longer 
degradation rates of PLLA, may mean that there may be an inflammatory response due 
the acid produced during the degradation, which is not seen when using the PGA 
scaffold material as this was already degraded before implantation. 
6.5 In Vivo Experiments 
In Section 5.3 it can be seen that the hypertrophic constructs did not mineralise during 
in vitro culture (Figure 5-13), however, the potential of these constructs to mineralise 
and be remodelled into bone in vivo needed to be assessed. It was decided to use the 
PGA scaffold material during these in vivo experiments as we were interested in the 
ability of hypertrophic chondrocyte construct to promote bone formation in a healing 
bone defect compared to an empty defect and therefore did not want any scaffold 
material remaining which may either aid in defect healing or cause an inflammatory 
response.  
At week 4 significantly increased bone regeneration within the cranial defect was 
observed using both the ‘living’ and decellularised constructs. However, the BM-MSC 
re-seeded constructs failed to significantly increase regeneration within the defect at 
week 4 (Figure 5-46 and Figure 5-47). The histological analysis of the defects highlights 
the importance of vascularisation in the regeneration of bone, since a vascular network 
was present within the implanted constructs (Figure 5-48). This need for initial 
vascularisation before mineralisation can proceed throughout the construct may 
explain the lack of mineralisation observed during the in vitro culture. Alcian blue 
staining of construct sections illustrated the degradation of the hypertrophic cartilage 
matrix around the areas of vascularisation (Figure 5-49).  
Previous research has highlighted the importance of endothelial progenitors and 
haematopoietic stem cells which express CD34+ for the neovascularisation of fractures 
and subsequent fracture healing (Matsumoto et al., 2008). Interestingly, Olmsted-Davis 
et al observed that CD34+ cells are able to generate osteogenic cells, which express 
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both osteocalcin and alkaline phosphatase (Olmsted-Davis et al., 2003). The decrease 
in ECM observed around the vascularisation of the graft can be attributed to the 
activity of MMPs expressed by and around areas of vascularisation. As discussed in 
Section 6.4.3 MMP-13 is expressed by hypertrophic chondrocytes and degrades the 
collagen type II present in the ECM. MMP-9 (gelatinase B) has been shown to be 
particularly important in its degradation of collagens within the ECM of hypertrophic 
cartilage (Vu et al., 1998). This highlights the importance of the expression of growth 
factors, such as VEGF, within the grafts in order to recruit the CD34+ cells from the 
bone marrow, to the peripheral blood and finally to areas of neovascularisation 
(Gerber et al., 1999).  
By week 8, significantly increased bone regeneration is once again observed by both 
the ‘living’ and decellularised constructs, with 22.94 % and 30.73 % bone volume seen 
within the defects respectively. At week 8 the repair of the living defects is seen to be 
less, than that of the decellularised construct although this decrease did not reach 
statistical significance (Figure 5-50 and Figure 5-51). Histological analysis of the defects 
showed the formation of bone within the defects treated with both ‘living’ and 
decellularised constructs (Figure 5-52).  
Bone formation originates from the periphery of the all the defects including the 
untreated defects. Previous research has shown that bone regeneration in cranial 
defects mainly occurs at the periphery of the defect, due to the increased mechanical 
stability at these locations (Hammerle et al., 1995). The larger the cranial defect the 
more this bone regeneration is marginalised and pushed towards the periphery of 
defects. The implantation of the graft materials in to the defect will increase the 
mechanical stability of the injury site. This increase in stability alone will allow for an 
increase in bone healing across the site of injury. In some of the defects bony islands 
are observed within the grafts materials throughout the defects and are established 
around the blood vessels and bone is formed out from these locations. This may be 
due to the influx of osteoblasts and monocyte-derived osteoclasts to regulate bone 
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formation through the blood vessels (Gerber and Ferrara, 2000).  The formation of 
bony islands within the grafts increases the mechanical stability of the defect, which 
should in turn accelerate the rate of bone regeneration within the defect (Hammerle et 
al., 1995). The decellularised grafts exhibit early vascularisation and bony islands form 
within the defect, this increase in bony island formation will increase the mechanical 
stability of the injury site and should therefore increase bone formation.   
There are a couple of possible hypotheses for the increase in bone regeneration 
observed using the decellularised graft. It has been reported that hypertrophic 
chondrocytes within the growth plate apoptose before mineralisation can proceed. The 
apoptosis of chondrocytes before implantation through the decellularisation of the 
graft may therefore increase the rate at which mineralisation can occur. There are also 
possible immunogenic reasons for the decrease in regeneration seen within the ‘living’ 
graft. The rats used in the in vivo experiments are relatives of the rats used for in vitro 
graft production it is possible that there is an inflammatory or a graft vs. host response 
to the graft, which will impair the repair of the defect. Toben et al observed that the 
expression of pro-inflammatory cytokines, such as tumour necrosis factor- alpha (TNF-
α), produced by lymphocytes in the adaptive immune system impairs bone 
regeneration in fractures.   
By week 12, both the ‘living’ and decellularised constructs had comparable bone 
regeneration (38.48 % and 38.59 % respectively), which was significantly greater than 
that seen in the untreated defect (7.56 %) (Figure 5-55). Therefore, by week 12 of in 
vivo implantation both ‘living’ and decellularised constructs had equivalent potential 
for bone regeneration. The MSC re-seeded constructs, however, while initiating some 
bone regeneration (21.22 %) did not reach statistical significance.  
As discussed in the literature review the use of BM-MSCs for bone regeneration has 
been well documented (Section 2.4 and 2.5.1). The bone regeneration by the BM-MSCs 
re-seeded decellularised construct, while increased compared to the empty defect, was 
slower than when using other types of constructs. Previously, it was hypothesised that 
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healing could be impaired by an inflammatory response however; BM-MSCs have an 
immature immune system which decreases the risk of an allogeneic immune reaction. 
The decrease in bone regeneration, therefore, cannot be attributed to an inflammatory 
response caused by the BM-MSCs re-seeded on the decellularised constructs. Little 
research has been performed on the differentiation of BM-MSCs on decellularised 
hypertrophic cartilage and therefore, the mechanisms which delay the regeneration of 
bone. It can be hypothesised that as the BM-MSCs differentiate down a chondrogenic 
lineage, they progress through a hyaline phenotype, which produce factors which can 
inhibit vascularisation of cartilage and this may account for the delay in bone 
regeneration as vascularisation of the graft is essential for bone regeneration. The 
multi-lineage potential of BM-MSCs may also contribute to the delay in bone 
regeneration, as once implanted it is not known which lineage the BM-MSC will 
differentiate down. The BM-MSCs may also not be able to survive within the hypoxic 
conditions found within the wound bed. More research is therefore required to 
decipher the fate of the BM-MSCs after implantation and whether further in vitro 
differentiation on the graft would be advantageous for bone regeneration. 
The potential of a decellularised hypertrophic cartilage to regenerate bone could 
provide an interesting new clinical approach to bone repair. The removal of both 
cellular and genetic material from the construct enables the formation of an allogeneic 
graft, leading to a potential ‘off the shelf’ therapy. It may also mean that these 
constructs could be made xenogenically and therefore, human donor tissue, would not 
be required. The use of a xenogeneic graft, however, would require more a stringent 
decellularisation protocol, in order to ensure further removal of genetic material and 
fully remove the immune response to the graft. However it is essential that the ECM 
and the growth factors which are present are not disrupted as this will impair the grafts 
ability to regenerate bone.  
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6.6 Bioreactor Culture 
As discussed in the literature review (Section 2.5.4) the flow regime within the culture 
system of hypertrophic cartilage grafts is important and the use of bioreactors for the 
production of tissue in vitro and for tissue-engineering may become essential. 
Bioreactors have the ability to standardise cultures and limit the amount of operator 
variability during in vitro culture periods giving rise to the reproducible tissue 
production. This will be essential when looking for regulatory approval for future 
tissue-engineered therapies.  
Due to the flow of media within the bioreactor the PLLA/calcium phosphate scaffold 
material was used as it has slower rate of degradation when compared to the PGA 
scaffold material which loses its’ tensile strength within two weeks of semi-static 
culture. It was therefore decided that under bioreactor culture conditions the PGA 
scaffold material may lose strength before sufficient ECM could be formed, decreasing 
the size and quality of the constructs produced. 
The use of fluid flow has been shown to have an positive effect on the accumulation of 
GAG and collagen within the ECM of cartilage grafts (Davisson et al., 2002). This effect 
was highlighted by the decrease in percentage GAG incorporated into the ECM of 
constructs formed using static conditions, compared to both the semi-static culture 
systems (Figure 5-61). The lack of ECM production in static conditions explains why all 
3D culture was performed on a gently oscillating, shaker plate set at 30 rpm. It is 
believed that this change in ECM production is modulated by the mobilisation of 
intracellular calcium signalling, caused by fluid flow, which results in an increase in cell 
proliferation and ECM production (Yellowley et al., 1997). The use of the bioreactor 
gave comparable GAG accumulation within the ECM of constructs, when compared to 
the semi-static culture system. Bioreactors must be able to support the proliferation 
and differentiation of the chondrocytes by providing efficient nutrient exchange as well 
as provide the fluid flow required for increased ECM accumulation. It is important, 
however, that this fluid flow does not produce high levels of shear stress which is 
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detrimental to the cells and would inhibit ECM accumulation. A flow rate of 110 μl 
minute-1 led to an increased chondrocyte proliferation without shear detachment of 
cells or a change in morphology in a 2D culture system (unpublished data).  
Bioreactor culture was shown to produce fully hypertrophic grafts, with expression of 
collagen type X and alkaline phosphate with the ECM of the grafts, co-localised with 
chondrocytes with a large morphology (Figure 5-62). Accumulation of GAG within the 
ECM was observed to be significantly higher when compared to the semi-static 
conditions used previously in section 5.3 (Figure 5-62). Use of the bioreactor also 
produced chondrocytes expressing slightly higher levels of collagen type X and 
significantly higher levels of alkaline phosphatase when compared to semi-static 
culture conditions (Figure 5-65 and Figure 5-66 respectively). The use of the bioreactor 
was also shown to significantly downregulate the expression of collagen type II (Figure 
5-64). 
The changes observed may be due to the type of flow present within bioreactor when 
compared to that seen on the shaker plate and the shear forces associated with it. Mild 
cyclic shear stress has been shown to accelerate endochondral ossification and lead to 
an increase in collagen type X and runx2 expression (Gawlitta et al., 2010, Wong et al., 
2003) during hypertrophic differentiation. The shear in the bioreactor is linear and 
occurs across the top surface of the constructs, so the majority of the chondrocytes 
exist in a low shear environment, whereas the shear experienced by the graft in the 
semi-static conditions is more turbulent and occurs all over the surface of the graft. 
The higher area and the more turbulent nature of shear stress experienced by the 
chondrocytes may be detrimental to the production of GAG in the graft. The shear 
stresses experienced by the chondrocytes within the scaffold material will alter 
throughout the differentiation culture as the chondrocytes differentiate. Initially the 
chondrocytes will attach to the microfibers with a flattened morphology, however as 
they increase in volume they will expand and bridge between the scaffold fibers 
making them more susceptible to shear stress. Therefore the laminar, low wall shear 
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stresses observed within the bioreactor maybe more suited to the larger morphology 
of hypertrophic chondrocytes in the later stages of the culture when compared to the 
more turbulent flow in the semi-static conditions. Turbulent flow conditions have been 
shown to be more shear damaging to cells than laminar flow shear. Although the 
turbulent flow within the semi static environment is low, the laminar flow bioreactor 
seems to support better chondrocyte differentiation and GAG accumulation.   
Use of this fluid flow bioreactor produced a high quality hypertrophic construct which 
could potentially be implanted in vivo. Therefore, bioreactors may become essential 
when looking at the clinical development of an engineered tissue in vitro, as the 
products will need to be reproducible, safe and economically competitive (Chen and 
Hu, 2006).  
6.7 Serum-Free Media 
Serum, is an important method of delivering growth factors for both cell maintenance 
and proliferation during in vitro culture (Brunner et al., 2010). As discussed in Section 
6.2, serum is a highly variable additive for culture media as its composition is 
dependent on the species (e.g. animal or human) and source of the donor(s); which in 
terms of FCS, from the bovine herd from which the serum is obtained. Every batch of 
FCS will have slightly different concentrations of growth factors, hormones, proteins, 
enzymes, fatty acids and lipids, vitamins and trace elements (Brunner et al., 2010). This 
variance can affect both the ability of cells to proliferate and differentiate. During the 
batch testing of FCS (Section 5.2), the sera had differing significant effects not only the 
amount of ECM produced during pellet culture, but also the ability for the 
chondrocytes to differentiate and mature into hypertrophic chondrocytes on a PGA 
scaffold material. Some of the sera completely inhibited or failed promote the 
hypertrophic differentiation of the chondrocytes (Figure 5-7), highlighting the 
problems associated with serum variability during tissue-engineering. 
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The variability of FCS and its impact on the differentiation of chondrocytes was the 
primary reason for looking into developing a serum-free media (Section 5.2 and 6.2). 
However, there was also a secondary reason; that of a regulatory requirement for a 
defined medium in developing an advanced tissue engineering medicinal product. The 
ideal end point of this research is to produce a clinically applicable treatment for large 
bone defects; therefore it is important to remove serum from the culture of tissue 
constructs as this will be a large step towards making the culture process highly 
reproducible. 
All serum-free media investigated contained BSA, which is adsorbed to the polymer 
surface of the PGA and allows for cell adhesion and the spreading of the cells on the 
scaffold fibres. While BSA only gives a 5% of cell spreading compared to fibronectin 
(lemons et al, 2012), it does aid cellular adhesion to the PGA in a serum-free 
environment where the plethora of proteins present in serum, which usually allow to 
cell attachment, are removed.  
Serum-free media 1 illustrated that the addition of FCS components was essential for 
the development of ECM in the constructs. The removal of FCS from the media, 
without making any growth factor substitutions to support cell survival and 
proliferation, resulted in the formation of a small construct with  a significantly lower 
GAG  content (1.94 % of ECM dry weight) within the ECM of the constructs, when 
compared to those seen when using serum-containing media (12.91 % ECM dry 
weight)(Figure 5-67). Limited hypertrophic differentiation was also observed with 
serum-free medium-1, the chondrocytes showed an increase in cell volume, but lacked 
expression of hypertrophic markers, collagen type X and alkaline phosphatase (Figure 
5-68). Therefore, additions of growth factors and/or hormones to the culture media 
were vital to replace the role of FCS in order to provide support for cell survival, 
proliferation and subsequent hypertrophic differentiation of the chondrocytes.  
ITS has previously been used as a basic cell culture addition when creating a serum-free 
cell culture media (van der Valk et al., 2010, Chua et al., 2005). Therefore ITS was 
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added to the serum-free media to give serum-free medium-2. This medium enabled 
attachment, proliferation and hypertrophic differentiation of the chondrocytes within 
the constructs (Figure 5-69). Serum-free media 2 resulted in constructs with 
significantly higher percentage of GAG in the ECM when compared to serum-free 
media 1 and comparable to those seen when using normal FCS media (Figure 5-67). 
The removal of FCS and its replacement with ITS also caused a significant upregulation 
of collagen type X gene expression by the chondrocytes within the construct at day 42. 
In these experiments, the commercial ITS preparation used was composed of 
recombinant human insulin, human transferrin (substantially iron-free), sodium 
selenite, linoleic acid, oleic acid and bovine serum albumin (Section 4.2.3.5), which 
have all been shown have been shown to influence cells during in vitro culture. At the 
dilution used the final concentrations of these agents in the culture media were: insulin 
(10 μg.mL-1), transferrin (5.5 μg.mL-1), selenium (5 ng.mL-1), and linoleic (4.7 μg.mL-1) 
and oleic (4.7 μg.mL-1) acids.  
The addition of transferrin is important for the maintenance of mammalian cells during 
in vitro culture. Transferrin is a homologous iron-binding glycoprotein that enables free 
iron to be sequestered and transported into cells, regulating the bioavailability of iron 
to the cells (Brandsma et al., 2010). Iron is important in cell culture as it supports 
several metabolic processes, such as  DNA synthesis and oxygen transport (Richardson 
and Ponka, 1997), as well as being closely linked with cell proliferation (Laskey et al., 
1988). Also non bound iron can cause free radical formation, which in turn causes 
tissue damage (Conrad et al., 1999). Selenium is an essential trace metal in cell culture 
for normal cell development and growth. It is required to be incorporated into 
essential seleno-enzymes which protect cells against oxidative damage (Saito et al., 
2003, Helmy et al., 2000). Linoleic acid is an unsaturated fatty acid which cannot be 
produced by cells and therefore these fatty acids along with others, such as oleic acid, 
are a necessary media addition. Not only are these acids important elements in the 
formation of cellular structures but are required as precursors to other molecules such 
as phospholipids and vitamins as well as allowing for long term energy storage within 
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the cells through the formation of triglycerides (Hewlett, 1991). Insulin whilst being 
important for the differentiation of the chondrocytes down a hypertrophic lineage 
(Bohme et al., 1992a) and also has an important role in cell survival as it regulates the 
uptake, utilization and storage of glucose, amino acids and fatty acids while inhibiting 
the breakdown of glycogen, protein and fat (Hewlett, 1991). ITS is therefore essential 
for the serum-free differentiation of the chondrocytes as it not only supports cell 
attachment, survival and proliferation but it also provides the insulin required to 
initiate the increase in cellular volume and hypertrophic differentiation. 
Thyroxine was added to the media as thyroid hormones have been shown to have an 
important effect on chondrocyte hypertrophic differentiation as discussed in Section 
6.2. Thyroxine was shown by Robson et al to induce hypertrophic differentiation 
chondrocytes in a serum-free media (Robson et al., 2000). Thyroxine was incorporated 
into serum-free media 3 (Section 0).   Use of serum-free medium 3 did not cause in a 
significant increase in the amount of GAG present within the ECM when compared to 
serum-free media 2 (Figure 5-67). However, both the staining and the mRNA 
expression for alkaline phosphatase were significantly increased (Figure 5-70 and 
Figure 5-73). Interestingly, collagen type X gene expression (Figure 5-72) was decreased 
although not significantly when compared to serum-free media 2 although this effect 
did not reach statistical significance. 
Current hypotheses suggested that the thyroid hormones act through the Wnt/β-
Catenin signalling pathway to induce the terminal differentiation of the chondrocytes 
(Figure 6-1) (Wang et al., 2007). Wang et al demonstrated that after addition of thyroid 
hormone to chondrocytes cultured as cell pellets, induced an increased accumulation 
of β-Catenin and up-regulation of Wnt-4 and runx2 mRNA expression after 4 or 5 days 
(Wang et al., 2007). Bohme et al observed that the addition of thyroxine had a positive 
effect on the expression of collagen type X and alkaline phosphatase (Bohme et al., 
1992a). In the study reported in this thesis, collagen type X gene expression was not 
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increased when constructs were cultured with thyroxine; however, the alkaline 










Addition of thyroxine to the serum-free media enabled a higher gene expression of 
alkaline phosphatase, when compared to other media (Figure 5-73). As discussed 
previously, alkaline phosphatase is essential for the degradation of PPi within the 
mineralising tissue, therefore it can be hypothesised that the use of serum-free media 
3 would enable an increased rate of mineralisation in vivo.   
Figure 6-1: Thyroid hormone activation of the Wnt signalling pathway leading to the 













Tissue-engineering a new graft material using the endochondral ossification pathway 
has been shown to have potential for the regeneration of bone tissue in challenging 
defects (Section 0). This research has advanced this tissue-engineering approach by 
investigating the effect of serum, scaffolds and culture conditions on the hypertrophic 
differentiation in vitro, as well as examining the potential of these hypertrophic tissue-
engineering grafts to regenerate bone defects in vivo. After careful analysis and 
discussion of results, the following conclusions were reached:  
 An electrospun PLLA scaffold was produced and was successfully modified to 
incorporate both hydroxyapatite and brushite on and in between the scaffold 
fibres. The addition of a calcium phosphate increased the hydrophilicity of the 
electrospun PLLA scaffold material. 
 FCS had a significant effect on construct quality, not only on the amount of GAG 
accumulated within the grafts but also on the terminal differentiation of the 
chondrocytes. While it is well-known that FCS has a significant effect of cells 
during in vitro culture, it was essential that this work was carried out to ensure 
that hypertrophic differentiation of the nasal chondrocytes could be repeated 
successfully.  
 The electrospun PLLA did not support the formation of a hypertrophic 
chondrocyte graft under the conditions used. The electrospun PLLA/calcium 
phosphate and PGA scaffold materials, however, did reproducibly support the 
formation of a high quality hypertrophic chondrocyte graft with the expression 
of hypertrophic markers co-located with chondrocytes with a large cellular 
morphology.  
 Measurement of gene and protein expression demonstrated the different 
stages of differentiation throughout the 42 day culture period, with collagen 
type II and sox9 being downregulated as the chondrocytes differentiate toward 
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an Ihh expressing pre-hypertrophic phenotype at day 21, before becoming fully 
hypertrophic with peaks in runx2 at day 28 and collagen type X and alkaline 
phosphatase expression at day 35.  
 Hypertrophic cartilage constructs were able to promote bone regeneration in 
vivo, over the control (construct and scaffold-free defect) in a healing cranial 
bone defect model. Vascularisation of the constructs was required for 
subsequent bone formation with in the defect. 
 Decellularised hypertrophic cartilage constructs were also able to promote 
bone regeneration in vivo. This potential for a decellularised hypertrophic 
cartilage graft has exciting clinical promise for an allogeneic, off the shelf 
therapy for bone regeneration. 
 Bioreactor culture increased the GAG content within the ECM of the constructs 
when compared to semi-static culture; there was also an increase in alkaline 
phosphatase expression at day 42. Therefore, the use of the flow bioreactor 
may be advantageous not only for culture standardisation and regulatory 
approval but also for the production of a high quality hypertrophic cartilage 
tissue graft. 
 Addition of ITS and thyroxine to the serum-free culture enabled the 
chondrocytes to reproducibly undergo hypertrophic differentiation. Removal of 
FCS is an important step forward in making this research more clinically 
applicable as in order to gain regulatory approval it will be necessary to use a 
defined culture media.  
To summarise, this work has substantially added to knowledge of hypertrophic 
differentiation of nasal chondrocytes and the ability of hypertrophic tissue engineered 
hypertrophic grafts to be used to regenerate bone tissue within complex or large 
defects. 
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8 Future Work  
The research presented in this thesis demonstrated the ability of rat nasal 
chondrocytes to produce a tissue-engineered hypertrophic chondrocyte graft which 
can regenerate bone tissue in vivo. More research, however, is required in order to 
make this a clinically applicable therapy for the treatment of non-union fractures or 
large defects. 
 The gene and protein expression of the chondrocytes during in vitro culture of 
tissue engineered constructs has provided insights into hypertrophic 
differentiation pathway of the cells. Further investigation, however, into gene 
expression both at the initial stages to examine PTHrP expression and at the 
final stages to investigate the expression of VEGF, osteocalcin and osteopontin, 
would be helpful. Research in this area, especially towards the end of the 
culture period may be able to explain the failure of the hypertrophic grafts to 
mineralise in vitro.   
 While the hypertrophic constructs were shown to remodel into bone tissue in 
vivo, cartilage mineralisation in vitro did not occur in this study. The histological 
data from the in vivo experiments suggested that vascularisation and the 
recruitment of endothelial cells into the graft, was essential for the bone 
formation observed. A co-culture of endothelial cells with the chondrocytes 
may therefore enable cartilage mineralisation in vitro.  
 The PLLA/calcium phosphate scaffold material was able to support the 
hypertrophic differentiation of chondrocytes in vitro. The ability of these grafts 
to heal defects in vivo was not assessed. Therefore, investigation of the ability 
of a hypertrophic cartilage graft grown on the PLLA/calcium phosphate scaffold 
material to increase bone regeneration in vivo, is therefore required. The ability 
for the PLLA/calcium phosphate scaffold material on its own to regenerate 
defects should also be investigated due to its increased osteogenic potential. 
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 The decellularised hypertrophic cartilage graft enabled bone regeneration at a 
slightly increased rate over that of the ‘living’ graft; while this is an exciting new 
development in bone tissue-engineering, further work needs to be performed 
in order further develop this method. Optimisation of the decellularisation 
technique is required to further increase DNA removal without adversely 
affecting the ECM composition or ultra-structure. Further reduction of DNA 
from the graft would further decrease the chance of viral transmission or an 
inflammatory response. It would also be interesting to investigate a developing 
a porcine or bovine decellularised graft, which could be utilised as a cell-free 
xenogeneic graft material for clinical applications in bone regeneration. 
 The use of a decellularised graft reseeded with MSCs induced bone 
regeneration, however, this was at a slower rate than the other grafts used. 
Therefore, it would be interesting to investigate the fate of the MSC on the 
decellularised hypertrophic cartilage both in vitro and in vivo, to help explain 
the delay in bone regeneration observed. Other cell types could also be used to 
reseed the decellularised graft, such as chondrocytes and endothelial cells. 
 A serum-free media was developed in this research which resulted in 
production of hypertrophic cartilage grafts. While this is a step forward in 
producing a defined media which is not reliant on the use of highly variable FCS, 
to produce a clinically applicable cellularised graft it is necessary to use a 
defined, serum-free, animal-free media. Therefore, future work on the removal 
of animal products from the media is essential to reduce a risk of viral 
transmission. 
 The preliminary studies using the Quasi-vivo® flow bioreactor produced 
hypertrophic cartilage grafts with higher percentages of GAG within the ECM 
and a higher expression of alkaline phosphatase. Further work needs to be 
performed to ensure that these results are reproducible under the defined flow 
conditions used in section 5.6. Further work using the bioreactor under 
different flow conditions would also be interesting as it has been suggested that 
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cyclic shear may increase both collagen type X and alkaline phosphatase 
expression in hypertrophic chondrocytes. 
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